<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cerebrolysin for acute ischaemic stroke - Ziganshina, LE - 2023 | Cochrane Library</title> <meta content="Cerebrolysin for acute ischaemic stroke - Ziganshina, LE - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007026.pub7/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cerebrolysin for acute ischaemic stroke - Ziganshina, LE - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007026.pub7/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007026.pub7" name="dc.identifier" scheme="DOI"/> <meta content="Cerebrolysin for acute ischaemic stroke" name="citation_title"/> <meta content="Liliya Eugenevna Ziganshina" name="citation_author"/> <meta content="lezign@mail.ru" name="citation_author_email"/> <meta content="Tatyana Abakumova" name="citation_author"/> <meta content="Kazan (Volga region) Federal University" name="citation_author_institution"/> <meta content="Dilyara Nurkhametova" name="citation_author"/> <meta content="Federal State Budgetary Educational Institution of Continuing Professional Education “Russian Medical Academy of Continuing Professional Education”, The Ministry of Health of the Russian Federation (RMANPO)" name="citation_author_institution"/> <meta content="Kristina Ivanchenko" name="citation_author"/> <meta content="St. Alexis Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD007026.pub7" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007026.pub7/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007026.pub7/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007026.pub7/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amino Acids [adverse effects]; *Ischemic Stroke [chemically induced, drug therapy]; Peptides; *Stroke [chemically induced, drug therapy]; Swine" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007026.pub7&amp;doi=10.1002/14651858.CD007026.pub7&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007026\x2epub7\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007026\x2epub7\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","ms","id","fa","pl","fr","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007026.pub7",title:"Cerebrolysin for acute ischaemic stroke",firstPublishedDate:"Oct 11, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007026.pub7&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007026.pub7';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007026.pub7/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007026.pub7/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007026.pub7%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007026.PUB7" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007026.pub7/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007026.PUB7" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007026.pub7/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007026.pub7/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3134 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007026.pub7" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0072"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-sec-0066"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/appendices#CD007026-sec-0077"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/supinfo/CD007026-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/supinfo/CD007026-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cerebrolysin for acute ischaemic stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#CD007026-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Liliya Eugenevna Ziganshina</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#CD007026-cr-0005">Tatyana Abakumova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#CD007026-cr-0006">Dilyara Nurkhametova</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information#CD007026-cr-0007">Kristina Ivanchenko</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information/en#CD007026-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007026.pub7">https://doi.org/10.1002/14651858.CD007026.pub7</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007026-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007026-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007026-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007026-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007026-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007026-abs-0006">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007026-abs-0001" lang="en"> <section id="CD007026-sec-0001"> <h3 class="title" id="CD007026-sec-0001">Background</h3> <p>Cerebrolysin is a mixture of low‐molecular‐weight peptides and amino acids derived from porcine brain, which has potential neuroprotective properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and other Asian and post‐Soviet countries. This is an update of a review first published in 2010 and last updated in 2020. </p> </section> <section id="CD007026-sec-0002"> <h3 class="title" id="CD007026-sec-0002">Objectives</h3> <p>To assess the benefits and harms of Cerebrolysin or Cerebrolysin‐like agents for treating acute ischaemic stroke. </p> </section> <section id="CD007026-sec-0003"> <h3 class="title" id="CD007026-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Trials Register, CENTRAL, MEDLINE, Embase, Web of Science Core Collection, with Science Citation Index, and LILACS in May 2022 and a number of Russian databases in June 2022. We also searched reference lists, ongoing trials registers, and conference proceedings. </p> </section> <section id="CD007026-sec-0004"> <h3 class="title" id="CD007026-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin‐like agents started within 48 hours of stroke onset and continued for any length of time, with placebo or no treatment in people with acute ischaemic stroke. </p> </section> <section id="CD007026-sec-0005"> <h3 class="title" id="CD007026-sec-0005">Data collection and analysis</h3> <p>Three review authors independently applied the inclusion criteria, assessed trial quality and risk of bias, extracted data, and applied GRADE criteria to the evidence. </p> </section> <section id="CD007026-sec-0006"> <h3 class="title" id="CD007026-sec-0006">Main results</h3> <p>Seven RCTs (1773 participants) met the inclusion criteria of the review. In this update we added one RCT of Cerebrolysin‐like agent Cortexin, which contributed 272 participants. </p> <p>We used the same approach for risk of bias assessment that was re‐evaluated for the previous update: we added consideration of the public availability of study protocols and reported outcomes to the selective outcome reporting judgement, through identification, examination, and evaluation of study protocols. </p> <p>For the Cerebrolysin studies, we judged the risk of bias for selective outcome reporting to be unclear across all studies; for blinding of participants and personnel to be low in three studies and unclear in the remaining four; and for blinding of outcome assessors to be low in three studies and unclear in four studies. We judged the risk of bias for generation of allocation sequence to be low in one study and unclear in the remaining six studies; for allocation concealment to be low in one study and unclear in six studies; and for incomplete outcome data to be low in three studies and high in the remaining four studies. The manufacturer of Cerebrolysin supported three multicentre studies, either totally, or by providing Cerebrolysin and placebo, randomisation codes, research grants, or statisticians. We judged two studies to be at high risk of other bias and the remaining five studies to be at unclear risk of other bias. We judged the study of Cortexin to be at low risk of bias for incomplete outcome data and at unclear risk of bias for all other domains. </p> <p><b>All‐cause death:</b> Cerebrolysin or Cortexin probably result in little to no difference in all‐cause death (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.65 to 1.41; 6 trials, 1689 participants; moderate‐certainty evidence). </p> <p>None of the included studies reported on poor functional outcome, defined as death or dependence at the end of the follow‐up period, early death (within two weeks of stroke onset), quality of life, or time to restoration of capacity for work. </p> <p>Only one study clearly reported on the cause of death: cerebral infarct (four in the Cerebrolysin and two in the placebo group), heart failure (two in the Cerebrolysin and one in the placebo group), pulmonary embolism (two in the placebo group), and pneumonia (one in the placebo group). </p> <p><b>Non‐death attrition (secondary outcome):</b> Cerebrolysin or similar peptide mixtures may result in little to no difference in non‐death attrition, but the evidence is very uncertain, with a considerable level of heterogeneity (RR 0.72, 95% CI 0.38 to 1.39; 6 trials, 1689 participants; very low‐certainty evidence). </p> <p><b>Serious adverse events (SAEs):</b> Cerebrolysin probably results in little to no difference in the total number of people with SAEs (RR 1.16, 95% CI 0.81 to 1.66; 3 trials, 1335 participants; moderate‐certainty evidence). This comprised fatal SAEs (RR 0.90, 95% CI 0.59 to 1.38; 3 trials, 1335 participants; moderate‐certainty evidence) and an increase in the total number of people with non‐fatal SAEs (RR 2.39, 95% CI 1.10 to 5.23; 3 trials, 1335 participants; moderate‐certainty evidence). In the subgroup of dosing schedule 30 mL for 10 days (cumulative dose 300 mL), the increase was more prominent (RR 2.87, 95% CI 1.24 to 6.69; 2 trials, 1189 participants). </p> <p><b>Total number of people with adverse events</b>: Cerebrolysin or similar peptide mixtures may result in little to no difference in the total number of people with adverse events (RR 1.03, 95% CI 0.92 to 1.14; 4 trials, 1607 participants; low‐certainty evidence). </p> </section> <section id="CD007026-sec-0007"> <h3 class="title" id="CD007026-sec-0007">Authors' conclusions</h3> <p>Moderate‐certainty evidence indicates that Cerebrolysin or Cerebrolysin‐like peptide mixtures derived from cattle brain probably have no beneficial effect on preventing all‐cause death in acute ischaemic stroke. Moderate‐certainty evidence suggests that Cerebrolysin probably has no beneficial effect on the total number of people with serious adverse events. Moderate‐certainty evidence also indicates a potential increase in non‐fatal serious adverse events with Cerebrolysin use. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007026-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007026-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007026-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007026-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007026-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007026-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD007026-abs-0009">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007026-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007026-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007026-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ro#CD007026-abs-0015">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007026-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007026-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007026-abs-0002" lang="en"> <h3>Cerebrolysin for acute ischaemic stroke</h3> <p><b>What did we want to know?</b> </p> <p>In this Cochrane Review, we wanted to find out how well a medicine called Cerebrolysin or other Cerebrolysin‐like agents work to treat a stroke. </p> <p><b>What is a stroke?</b> </p> <p>A stroke is a sudden attack of weakness that usually affects one side of the body. It happens when the flow of blood to part of the brain is cut off, stopping the supply of oxygen and nutrients to the brain cells, which is called ischaemia. If the supply of blood to the brain is stopped, brain cells begin to die. This can lead to brain injury, disability, and possibly death. </p> <p>Ischaemic strokes are the most common type of stroke. An ischaemic stroke happens when the flow of blood is blocked by a blood clot or a piece of fatty material in an artery. </p> <p><b>Why is this review important?</b> </p> <p>Strokes are a medical emergency, and urgent treatment is essential. Ischaemic strokes are usually treated with a combination of medicines to prevent and dissolve blood clots, reduce blood pressure, and lower cholesterol levels. </p> <p>Cerebrolysin, and the Cerebrolysin‐like agent Cortexin, are mixtures of proteins, peptides (short chains of amino acids) and amino acids (small molecules that combine to form a protein) purified from animal brains (cows and pigs). Some of the proteins in Cerebrolysin or Cortexin are found naturally in the human brain and may help to protect and repair brain cells. Cerebrolysin and Cortexin are commonly used in some countries as a treatment for stroke. </p> <p><b>What did we do?</b> </p> <p>We searched for studies looking at the use of Cerebrolysin or Cerebrolysin‐like agents to treat acute ischaemic stroke. We searched for randomised controlled studies, in which the treatment people receive is randomly decided, because these studies give the most reliable evidence about treatments. </p> <p>Search date: we included evidence published up to June 2022.</p> <p><b>What we found</b> </p> <p>We found seven studies in 1773 people who had had an acute ischaemic stroke. The studies looked at the effect of giving Cerebrolysin alongside medicines to prevent and dissolve blood clots (standard therapy) during the first 48 hours after a stroke. The studies compared this treatment with standard therapy alone or standard therapy plus a dummy treatment (placebo). </p> <p>The studies were conducted in hospitals in Austria, Croatia, the Czech Republic, Hungary, Russia, Slovakia, Slovenia, China, Hong Kong, Iran, Myanmar, and South Korea, and lasted from 28 days to 90 days. </p> <p><b>Results of our review</b> </p> <p>Adding Cerebrolysin or a Cerebrolysin‐like agent, Cortexin, to standard therapy probably adds no benefit to the risk of dying from any cause after a stroke (6 studies, 1689 people). </p> <p>We did not find enough evidence about how Cerebrolysin or the Cerebrolysin‐like agent Cortexin affected: </p> <p>• the risk of dying or needing continuing care at the end of the study;<br/>• the risk of dying within two weeks of having a stroke;<br/>• the time taken for people to be able to go back to work; or<br/>• people's well‐being (quality of life). </p> <p>We are uncertain whether adding Cerebrolysin to standard therapy made any difference to the numbers of people who dropped out of studies (6 studies, 1689 people). </p> <p>Cerebrolysin added to standard therapy probably made little or no difference to:</p> <p>• the total number of people who had serious unwanted effects (life‐threatening effects that could result in death, disability, or a longer hospital stay) (3 studies, 1335 people);<br/>• the number of serious unwanted effects that caused death (3 studies, 1335 people). </p> <p>However, more people given Cerebrolysin plus standard therapy probably had serious unwanted effects that did not kill them than those who were given standard therapy (alone or with placebo) (3 studies, 1335 people). </p> <p>Cerebrolysin or the Cerebrolysin‐like agent Cortexin may make little or no difference to the total number of people who had any unwanted effects (4 studies, 1607 people). </p> <p><b>Our confidence in the results</b> </p> <p>We are moderately confident (certain) in the results of this review. However, the evidence comes from a small number of studies. Three studies involved a pharmaceutical company that makes Cerebrolysin, which may have affected how those studies were designed, carried out, and reported. Our conclusions are likely to change if results from further studies become available. </p> <p><b>Conclusions</b> </p> <p>Adding Cerebrolysin or a Cerebrolysin‐like agent, Cortexin, to standard therapy after an acute ischaemic stroke probably: </p> <p>• does not reduce the risk of dying.</p> <p>Adding Cerebrolysin to standard therapy after an ischaemic stroke probably:</p> <p>• does not affect how many people have serious unwanted effects overall; but<br/>• increases the number of people with serious, non‐fatal unwanted effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007026-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007026-sec-0072"></div> <h3 class="title" id="CD007026-sec-0073">Implications for practice</h3> <section id="CD007026-sec-0073"> <p>This review indicates that Cerebrolysin and the Cerebrolysin‐like agent Cortexin probably result in little to no difference in deaths after acute ischaemic stroke. </p> <p>We found moderate‐certainty evidence that there is probably little to no difference between groups in the total number of people with serious adverse events, but there is a possible increase in the total number of people with non‐fatal serious adverse events with Cerebrolysin use. </p> <p>We note that there were deaths with the use of the Cerebrolysin‐like agent Cortexin in people with mild acute ischaemic stroke, while there were no deaths in the placebo group. </p> </section> <h3 class="title" id="CD007026-sec-0074">Implications for research</h3> <section id="CD007026-sec-0074"> <p>Future research should focus on systematic review of the harms of Cerebrolysin and Cerebrolysin‐like agents in acute ischaemic stroke and in its other potential uses. </p> <p>We advocate for no further trials of Cerebrolysin and Cerebrolysin‐like agents on the grounds that it would be unethical to recruit patients into a study that offers no potential benefit. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007026-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007026-sec-0008"></div> <div class="table" id="CD007026-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute ischaemic stroke<br/><b>Settings:</b> inpatient health facilities<br/><b>Intervention:</b> Cerebrolysin or Cortexin added to standard therapy<br/><b>Comparison:</b> placebo added to standard therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cerebrolysin/Cortexin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All‐cause death (follow‐up period up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> <p>47/767 (6.1%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> <p>53/922 (5.7%)</p> <p><b>3 fewer per 1000</b> </p> <p>(from 22 fewer to 22 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/>(0.65 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1689<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Non‐death attrition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b> </p> <p>111/767 (14.5%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> <p>80/922 (8.7%)</p> <p><b>58 fewer per 1000</b> </p> <p>(from 39 fewer to 152 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b> </p> <p>(0.38 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1689<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Total number of people with SAEs**</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> <p>50/668 (7.5%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> <p>58/667 (8.7%)</p> <p><b>12 more per 1000</b> </p> <p>(from 14 fewer to 47 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> </p> <p>(0.81 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> <p>42/668 (6.3%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> <p>38/667 (5.7%)</p> <p><b>6 fewer per 1000</b> </p> <p>(from 26 fewer to 24 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.59 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> <p>8/668 (1.2%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> <p>20/667 (3.0%)</p> <p><b>18 more per 1 000</b> </p> <p>(from 0 fewer to 49 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.39</b> </p> <p>(1.10 to 5.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total number of people with adverse events, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> <p>314/732 (42.9%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b><br/>339/875 (38.7%) </p> <p><b>42 fewer per 1000</b> </p> <p>(from 38 fewer to 55 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/>(0.92 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1607<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Death or dependence, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Early death (within 2 weeks of stroke onset)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>**<b>Results of the subgroup analysis:</b> </p> <p><b>Total number of people with SAEs, non‐fatal</b> </p> <p>A subgroup by Cerebrolysin dose and length of treatment (30 mL for 10 days), at the end of the follow‐up period: assumed risk 12 per 1000 7/600 (1.2%); corresponding risk 33 per 1000 20/589 (3.4%), 22 more per 1000 (from 3 more to 66 more) </p> <p><b>RR 2.86 (1.23 to 6.66)</b>; number of participants (studies) 1189 (2 RCTs) </p> <p>Certainty of the evidence ⊕⊕⊕⊝ <b>Moderate</b><sup>a</sup> </p> <p>_________________________</p> <p><sup>a</sup>We downgraded by one level for risk of bias because most information came from studies at low or unclear risk of bias, with high levels of exclusion from the final analyses, retrospective registration, and other methodological flaws as described in Assessment of risk of bias in included studies. The manufacturer of Cerebrolysin supported <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> and <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> by providing services including: provision of Cerebrolysin and placebo, randomisation codes, and statisticians. </p> <p><sup>b</sup>We downgraded by one level for inconsistency: heterogeneity with I<sup>2</sup> = 37% for the overall effect estimate owing to the opposite direction of effect estimate in the <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> study (high cumulative dose of Cerebrolysin), and heterogeneity with I<sup>2</sup> = 65% in the subgroup of two multicentre studies with the same dosing schedule (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>). </p> <p><sup>c</sup>We downgraded by one level for inconsistency and by one level for imprecision. Five trials contributed to the outcome non‐death attrition; we detected heterogeneity, with I<sup>2</sup> = 57% for the overall effect estimate and I<sup>2</sup> = 66% for subgroup differences, and heterogeneity with I<sup>2</sup> = 47% in the subgroup of two multicentre studies with the same dosing schedule (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>). The confidence intervals were wide. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007026-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007026-sec-0009"></div> <p>Effective, simple, and reliable treatment methods are urgently needed to reduce stroke mortality and disability. Many clinical trials and Cochrane Reviews have addressed the question of benefits and risks of potential pharmacological treatment options for acute ischaemic stroke. However, strategies with proven therapeutic effects and an acceptable benefit‐to‐risk ratio are still lacking. Potential strategies can be grouped according to the existing evidence of their benefits and harms determining their role in clinical practice. </p> <section id="CD007026-sec-0010"> <h3 class="title" id="CD007026-sec-0010">Evidence of benefit</h3> <p>Aspirin at a dose of 160 mg to 300 mg daily (orally or per rectum), started within 48 hours of onset of presumed ischaemic stroke, appears to be the only effective treatment for early secondary prevention, reducing the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications, and improving long‐term outcomes (<a href="./references#CD007026-bbs2-0089" title="MinhasJS , ChithiramohanT , WangX , BarnesSC , CloughRH , KadicheeniM , et al. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2022, Issue 1. Art. No: CD000029. [DOI: 10.1002/14651858.CD000029.pub4]">Minhas 2022</a>; <a href="./references#CD007026-bbs2-0109" title="SandercockPAG , CounsellC , TsengMC , CecconiE . Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD000029. [DOI: 10.1002/14651858.CD000029.pub3]">Sandercock 2014</a>). Despite the positive overall conclusions of a Cochrane Review, <a href="./references#CD007026-bbs2-0126" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD000213. [DOI: 10.1002/14651858.CD000213.pub3]">Wardlaw 2014</a>, and individual patient data meta‐analysis, <a href="./references#CD007026-bbs2-0051" title="EmbersonJ , LeesKR , LydenP , BlackwellL , AlbersG , BluhmkiE , et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet2014;384(9958):1929-35.">Emberson 2014</a>, of thrombolysis in acute ischaemic stroke, there is still some debate regarding the optimal use of intravenous recombinant tissue plasminogen activators (rtPA) (<a href="./references#CD007026-bbs2-0025" title="AlperBS , Malone-MosesM , McLellanJS , PrasadK , ManheimerE . Thrombolysis in acute ischaemic stroke: time for a rethink?BMJ2015;350:h1075. [DOI: 10.1136/bmj.h1075]">Alper 2015</a>). It is estimated that for every person with a good stroke outcome at six months, another person would have symptomatic intracranial bleeding, and for every three to four people without neurological deficits at six months, there is an excess of one death after thrombolysis (<a href="./references#CD007026-bbs2-0027" title="AppelrosP , TeréntA . Thrombolysis in acute stroke. Lancet2015;385(9976):1394. [DOI: 10.1016/S0140-6736(15)60714-0]">Appelros 2015</a>; <a href="./references#CD007026-bbs2-0041" title="BrunströmM , CarlbergB . Thrombolysis in acute stroke. Lancet2015;385(9976):1394–5. [DOI: 10.1016/S0140-6736(15)60715-2]">Brunström 2015</a>). The evidence is inadequate to conclude whether lower doses of thrombolytic agents are more effective than higher doses, whether one agent is better than another, or which route of administration is the best for treatment of people who have had an acute ischaemic stroke (<a href="./references#CD007026-bbs2-0125" title="WardlawJM , KoumellisP , LiuM . Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database of Systematic Reviews2013, Issue 5. Art. No: CD000514. [DOI: 10.1002/14651858.CD000514.pub3]">Wardlaw 2013</a>), or whether percutaneous vascular interventions offer any advantages over intravenous thrombolysis in terms of patient‐oriented outcomes (<a href="./references#CD007026-bbs2-0082" title="LindekleivH , BergeE , Bruins SlotKMH , WardlawJM . Percutaneous vascular interventions versus intravenous thrombolytic treatment for acute ischaemic stroke. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD009292. [DOI: 10.1002/14651858.CD009292.pub2]">Lindekleiv 2018</a>). </p> </section> <section id="CD007026-sec-0011"> <h3 class="title" id="CD007026-sec-0011">Evidence of harm</h3> <p>Glycoprotein IIb‐IIIa inhibitors (abciximab and tirofiban) increase the risk of intracranial haemorrhage without evidence of any reduction in death or disability in stroke survivors (<a href="./references#CD007026-bbs2-0047" title="CicconeA , MottoC , AbrahaI , CozzolinoF , SantilliI . Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD005208. [DOI: 10.1002/14651858.CD005208.pub3]">Ciccone 2014</a>). These data do not support their routine use in clinical practice. Abciximab contributed 89% of the total number of participants in the Cochrane Review (<a href="./references#CD007026-bbs2-0047" title="CicconeA , MottoC , AbrahaI , CozzolinoF , SantilliI . Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD005208. [DOI: 10.1002/14651858.CD005208.pub3]">Ciccone 2014</a>). Anticoagulants (standard unfractionated heparin, low‐molecular‐weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors) as immediate therapy for acute ischaemic stroke are not associated with net short‐ or long‐term benefit. Reduced rate of recurrent stroke, deep vein thrombosis, and pulmonary embolism with anticoagulant therapy is offset by the increased risk of intracranial haemorrhage and extracranial bleeding. The data do not support the routine use of any of the currently available anticoagulants in acute ischaemic stroke (<a href="./references#CD007026-bbs2-0038" title="BergeE , SandercockP . Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database of Systematic Reviews2002, Issue 4. Art. No: CD003242. [DOI: 10.1002/14651858.CD003242]">Berge 2002</a>; <a href="./references#CD007026-bbs2-0110" title="SandercockPAG , CounsellC , KaneEJ . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD000024. [DOI: 10.1002/14651858.CD000024.pub4]">Sandercock 2015</a>; <a href="./references#CD007026-bbs2-0111" title="SandercockPAG , LeongTS . Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD000119. [DOI: 10.1002/14651858.CD000119.pub4]">Sandercock 2017</a>; <a href="./references#CD007026-bbs2-0124" title="WangX , OuyangM , YangJ , SongL , YangM , AndersonCS . Anticoagulants for acute ischaemic stroke. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD000024. [DOI: 10.1002/14651858.CD000024.pub5]">Wang 2021</a>). Long‐term anticoagulant therapy in people with presumed non‐cardioembolic ischaemic stroke or transient ischaemic attack is not associated with any benefit, but there is a significant risk of bleeding (<a href="./references#CD007026-bbs2-0107" title="SandercockPAG , GibsonLM , LiuM . Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews2009, Issue 2. Art. No: CD000248. [DOI: 10.1002/14651858.CD000248.pub2]">Sandercock 2009</a>). </p> <p>Tirilazad, an amino steroid inhibitor of lipid peroxidation, increases the combined endpoint of 'death or disability' in people with acute ischaemic stroke (<a href="./references#CD007026-bbs2-0120" title="BathPM , IddendenR , BathFJ , OrgogozoJM , Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD002087. [DOI: 10.1002/14651858.CD002087]">TISC 2001</a>). Lubeluzole, an ion channel modulator of glutamate release that has a benzothiazole structure with potential neuroprotective properties, does not reduce death or dependency in acute ischaemic stroke patients; in contrast, it increases heart‐conduction disorders (Q‐T prolongation) (<a href="./references#CD007026-bbs2-0058" title="GandolfoC , SandercockP , ContiM . Lubeluzole for acute ischaemic stroke. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD001924. [DOI: 10.1002/14651858.CD001924]">Gandolfo 2002</a>). </p> </section> <section id="CD007026-sec-0012"> <h3 class="title" id="CD007026-sec-0012">Lack of evidence of benefit</h3> <p>Several treatment options that have been tested in clinical trials have not shown any evidence of benefit. The results of these trials have been systematically reviewed: corticosteroids (<a href="./references#CD007026-bbs2-0108" title="SandercockPAG , SoaneT . Corticosteroids for acute ischaemic stroke. Cochrane Database of Systematic Reviews2011, Issue 9. Art. No: CD000064. [DOI: 10.1002/14651858.CD000064.pub2]">Sandercock 2011</a>), calcium antagonists (<a href="./references#CD007026-bbs2-0135" title="ZhangJ , LiuJ , LiD , ZhangC , LiuM . Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD001928. [DOI: 10.1002/14651858.CD001928.pub3]">Zhang 2019</a>), haemodilution (<a href="./references#CD007026-bbs2-0043" title="ChangTS , JensenMB . Haemodilution for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD000103. [DOI: 10.1002/14651858.CD000103.pub2]">Chang 2014</a>), excitatory amino acid antagonists (including ion channel modulators and N‐methyl‐D‐aspartic acid; NMDA) (<a href="./references#CD007026-bbs2-0092" title="MuirKW , LeesKR . Excitatory amino acid antagonists for acute stroke. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD001244. [DOI: 10.1002/14651858.CD001244]">Muir 2003</a>), piracetam (<a href="./references#CD007026-bbs2-0102" title="RicciS , CelaniMG , CantisaniTA , RighettiE . Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD000419. [DOI: 10.1002/14651858.CD000419.pub3]">Ricci 2012a</a>), a free radical trapping agent NXY‐059 (<a href="./references#CD007026-bbs2-0117" title="ShuaibA , LeesKR , LydenP , GrottaJ , DavalosA , DavisSM , et al. NXY-059 for the treatment of acute ischemic stroke. New England Journal of Medicine2007;357(6):562-71.">Shuaib 2007</a>), and Cerebrolysin (<a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>). There is no evidence that colloids lead to lower odds of death or dependence after stroke compared with crystalloids (<a href="./references#CD007026-bbs2-0122" title="VisvanathanA , DennisM , WhiteleyW . Parenteral fluid regimens for improving functional outcome in people with acute stroke. Cochrane Database of Systematic Reviews2015, Issue 9. Art. No: CD011138. [DOI: 10.1002/14651858.CD011138.pub2]">Visvanathan 2015</a>). </p> </section> <section id="CD007026-sec-0013"> <h3 class="title" id="CD007026-sec-0013">Role in clinical practice</h3> <p>There is still inadequate evidence from randomised controlled trials for the following antithrombotic agents: oral antiplatelet drugs other than aspirin (clopidogrel, ticlopidine, cilostazol, satigrel, sarpolgrelate, KBT 3022, isbogrel) (<a href="./references#CD007026-bbs2-0089" title="MinhasJS , ChithiramohanT , WangX , BarnesSC , CloughRH , KadicheeniM , et al. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2022, Issue 1. Art. No: CD000029. [DOI: 10.1002/14651858.CD000029.pub4]">Minhas 2022</a>; <a href="./references#CD007026-bbs2-0109" title="SandercockPAG , CounsellC , TsengMC , CecconiE . Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD000029. [DOI: 10.1002/14651858.CD000029.pub3]">Sandercock 2014</a>), and the fibrinogen‐depleting agents ancrod and defibrase (<a href="./references#CD007026-bbs2-0074" title="HaoZ , LiuM , CounsellC , WardlawJM , LinS , ZhaoX . Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD000091. [DOI: 10.1002/14651858.CD000091.pub2]">Hao 2012</a>). </p> <p>The list of interventions of agents tested in clinical trials with subsequent Cochrane Reviews of results that document inadequate evidence to establish a role in clinical practice includes: ginkgo biloba (<a href="./references#CD007026-bbs2-0133" title="ZengX , LiuM , YangY , LiY , AsplundK . Ginkgo biloba for acute ischaemic stroke. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003691. [DOI: 10.1002/14651858.CD003691.pub2]">Zeng 2005</a>); gamma aminobutyric acid (GABA) receptor agonists (<a href="./references#CD007026-bbs2-0084" title="LiuJ , ZhangJ , WangLN . Gamma aminobutyric acid (GABA) receptor agonists for acute stroke. Cochrane Database of Systematic Reviews2018, Issue 10. Art. No: CD009622. [DOI: 10.1002/14651858.CD009622.pub5]">Liu 2018</a>); sonothrombolysis (<a href="./references#CD007026-bbs2-0103" title="RicciS , DiniaL , Del SetteM , AnzolaP , MazzoliT , CenciarelliS , et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2012, Issue 10. Art. No: CD008348. [DOI: 10.1002/14651858.CD008348.pub3]">Ricci 2012b</a>); glycerol (<a href="./references#CD007026-bbs2-0104" title="RighettiE , CelaniMG , CantisaniT , SterziR , BoysenG , RicciS . Glycerol for acute stroke. Cochrane Database of Systematic Reviews2004, Issue 2. Art. No: CD000096. [DOI: 10.1002/14651858.CD000096.pub2]">Righetti 2004</a>); mannitol (<a href="./references#CD007026-bbs2-0035" title="BereczkiD , FeketeI , PradoGF , LiuM . Mannitol for acute stroke. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD001153. [DOI: 10.1002/14651858.CD001153.pub2]">Bereczki 2007</a>); naftidrofuryl, a 5‐HT2 serotonergic antagonist (<a href="./references#CD007026-bbs2-0081" title="Leonardi-BeeJ , SteinerT , Bath-HextallF . Naftidrofuryl for acute stroke. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: CD005478. [DOI: 10.1002/14651858.CD005478.pub2]">Leonardi‐Bee 2007</a>); theophylline or methylxanthine derivatives (<a href="./references#CD007026-bbs2-0029" title="BathPMW . Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD000211. [DOI: 10.1002/14651858.CD000211.pub2]">Bath 2004a</a>; <a href="./references#CD007026-bbs2-0030" title="BathPMW , Bath-HextallFJ . Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD000162. [DOI: 10.1002/14651858.CD000162.pub2]">Bath 2004b</a>); nitric oxide donors (<a href="./references#CD007026-bbs2-0034" title="BathPMW , KrishnanK , AppletonJP . Nitric oxide donors (nitrates), L-arginine, or nitric oxide synthase inhibitors for acute stroke. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD000398. [DOI: 10.1002/14651858.CD000398.pub2]">Bath 2017</a>); blood pressure‐altering interventions (<a href="./references#CD007026-bbs2-0033" title="BathPMW , KrishnanK . Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews2014, Issue 10. Art. No: CD000039. [DOI: 10.1002/14651858.CD000039.pub3]">Bath 2014</a>; <a href="./references#CD007026-bbs2-0060" title="GeeganageC , BathPMW . Vasoactive drugs for acute stroke. Cochrane Database of Systematic Reviews2010, Issue 7. Art. No: CD002839. [DOI: 10.1002/14651858.CD002839.pub2]">Geeganage 2010</a>); prostacyclin and its analogues (<a href="./references#CD007026-bbs2-0031" title="BathPMW . Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD000177. [DOI: 10.1002/14651858.CD000177.pub2]">Bath 2004c</a>); buflomedil (<a href="./references#CD007026-bbs2-0131" title="WuS , ZengQ , LiuM , YangJ , HeS , LinS , et al. Buflomedil for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD009570. [DOI: 10.1002/14651858.CD009570.pub2]">Wu 2015</a>); vinpocetine (<a href="./references#CD007026-bbs2-0036" title="BereczkiD , FeketeI . Vinpocetine for acute ischaemic stroke. Cochrane Database of Systematic Reviews2008, Issue 1. Art. No: CD000480. [DOI: 10.1002/14651858.CD000480.pub2]">Bereczki 2008</a>); gangliosides (<a href="./references#CD007026-bbs2-0042" title="CandeliseL , CicconeA . Gangliosides for acute ischaemic stroke. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000094. [DOI: 10.1002/14651858.CD000094]">Candelise 2001</a>); colony‐stimulating factors (<a href="./references#CD007026-bbs2-0032" title="BathPMW , SpriggN , EnglandT . Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD005207. [DOI: 10.1002/14651858.CD005207.pub4]">Bath 2013</a>); stem cells (<a href="./references#CD007026-bbs2-0039" title="BoncoraglioGB , RanieriM , BersanoA , ParatiEA , Del GiovaneC . Stem cell transplantation for ischemic stroke. Cochrane Database of Systematic Reviews2019, Issue 5. Art. No: CD007231. [DOI: 10.1002/14651858.CD007231.pub3]">Boncoraglio 2019</a>); Chinese herbal medicines such as sanchi (<a href="./references#CD007026-bbs2-0045" title="ChenX , ZhouM , LiQ , YangJ , ZhangY , ZhangD , et al. Sanchi for acute ischaemic stroke. Cochrane Database of Systematic Reviews2008, Issue 4. Art. No: CD006305. [DOI: 10.1002/14651858.CD006305.pub2]">Chen 2008</a>), puerarin (<a href="./references#CD007026-bbs2-0083" title="LiuB , TanY , WangD , LiuM . Puerarin for ischaemic stroke. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD004955. [DOI: 10.1002/14651858.CD004955.pub3]">Liu 2016</a>), mailuoning (<a href="./references#CD007026-bbs2-0132" title="YangW , ShiZ , YangHQ , TengJ , ZhaoJ , XiangG . Mailuoning for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 1. Art. No: CD007028. [DOI: 10.1002/14651858.CD007028.pub3]">Yang 2015</a>), and tongxinluo (<a href="./references#CD007026-bbs2-0136" title="ZhuoQ , YangX , WuT , LiuG , ZhouL . Tongxinluo capsule for acute stroke. Cochrane Database of Systematic Reviews2008, Issue 4. Art. No: CD004584. [DOI: 10.1002/14651858.CD004584.pub2]">Zhuo 2008</a>); and the neuroprotective agent edaravone (<a href="./references#CD007026-bbs2-0053" title="FengS , YangQ , LiuM , LiW , YuanW , ZhangS , et al. Edaravone for acute ischaemic stroke. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD007230. [DOI: 10.1002/14651858.CD007230.pub2]">Feng 2011</a>). </p> </section> <section id="CD007026-sec-0014"> <h3 class="title" id="CD007026-sec-0014">Description of the condition</h3> <p>Ischaemic stroke occurs when the brain loses its blood and energy supply, resulting in damage to brain tissue; it is the brain equivalent of a heart attack. Most strokes (87%) are ischaemic as confirmed by computerised tomography (CT) scan (<a href="./references#CD007026-bbs2-0023" title="BenjaminEJ , MuntnerP , AlonsoA , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke disease statistics - 2019 update: a report from the American Heart Association. Circulation2019;139:e1-473. [DOI: 10.1161/CIR.0000000000000659]">AHA 2019</a>; <a href="./references#CD007026-bbs2-0024" title="TsaoCW , AdayAW , AlmarzooqZI , AlonsoA , BeatonAZ , BittencourtMS , et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation2022;145(8):e153–e639. [DOI: 10.1161/CIR.0000000000001052]">AHA 2022</a>). Worldwide 15 million people suffer a stroke every year; five‐and‐a‐half million people die, and another five million are left permanently disabled, placing a burden on family and community (<a href="./references#CD007026-bbs2-0127" title="World Health Organization. The Atlas of Heart Disease and Stroke. www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed November 2019).">WHO 2019a</a>). Stroke is one of the major causes of disability and mortality (<a href="./references#CD007026-bbs2-0023" title="BenjaminEJ , MuntnerP , AlonsoA , BittencourtMS , CallawayCW , CarsonAP , et al. Heart disease and stroke disease statistics - 2019 update: a report from the American Heart Association. Circulation2019;139:e1-473. [DOI: 10.1161/CIR.0000000000000659]">AHA 2019</a>; <a href="./references#CD007026-bbs2-0024" title="TsaoCW , AdayAW , AlmarzooqZI , AlonsoA , BeatonAZ , BittencourtMS , et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation2022;145(8):e153–e639. [DOI: 10.1161/CIR.0000000000001052]">AHA 2022</a>; <a href="./references#CD007026-bbs2-0059" title="GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology2019;18:439–58. [DOI: 10.1016/S1474-4422(19)30034-1]">GBD Stroke Collaborators 2019</a>; <a href="./references#CD007026-bbs2-0127" title="World Health Organization. The Atlas of Heart Disease and Stroke. www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed November 2019).">WHO 2019a</a>). It is the third most common cause of death after coronary disease and cancer. In 2014, the World Health Organization (WHO) stroke statistics registered the number of deaths from stroke to be more than 200,000 in the Russian Federation, as well as in China and in India, with the highest number of 1,652,885 in China and 517,424 in Russia in 2002 (<a href="./references#CD007026-bbs2-0127" title="World Health Organization. The Atlas of Heart Disease and Stroke. www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed November 2019).">WHO 2019a</a>). According to the Russian data, there were on average 3.52 and 3.27 cases per 1000 population registered in the Russian Federation in 2009 and 2010, respectively, and mortality was 1.19 and 0.96 per 1000 population in 2009 and 2010, with significant differences between different regions (<a href="./references#CD007026-bbs2-0072" title="GusevEI , Martynov MYu, KamtchatnovPR . Ischemic stroke: current status [Ishemichesky insult. Sovremennoye sostoyaniye problemy]. Nevrologiya [Neurology]2013;83(5):2-7.">Gusev 2013</a>). Standardised incidence was 2.39 (3.24 in men and 2.24 in women) per 1000 population (<a href="./references#CD007026-bbs2-0072" title="GusevEI , Martynov MYu, KamtchatnovPR . Ischemic stroke: current status [Ishemichesky insult. Sovremennoye sostoyaniye problemy]. Nevrologiya [Neurology]2013;83(5):2-7.">Gusev 2013</a>). In 2016 in Russia there were 345,861 stroke deaths (95% confidence interval (CI) 267,315 to 444,861), 676,846 incident cases (95% CI 607,894 to 746,828), and 6,082,727 disability‐adjusted life‐years (DALYs) (95% CI 4,773,920 to 7,736,480) (<a href="./references#CD007026-bbs2-0059" title="GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology2019;18:439–58. [DOI: 10.1016/S1474-4422(19)30034-1]">GBD Stroke Collaborators 2019</a>). The case fatality rate of stroke is 40.4% (61.4% for haemorrhagic stroke and 21.8% for ischaemic stroke). The northwest regions of Russia had the highest stroke incidence of 7.43 per 1000, followed by some cities in mid areas of the country (5.37 per 1000) and the far east (4.41 per 1000) (<a href="./references#CD007026-bbs2-0071" title="GusevEI , SkvortsovaVI , StakhovskaiaLV . Epidemiology of stroke in Russia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2003;Suppl 8:4-9.">Gusev 2003</a>; <a href="./references#CD007026-bbs2-0121" title="VilenskiiBS , IakhnoNN . The problem of cerebral stroke: its contemporary state. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk [Bulletin of the Russian Academy of Medical Sciences]2006;9-10:18-24.">Vilenskiĭ 2006</a>). The rate of recurrence of stroke was 30% (<a href="./references#CD007026-bbs2-0119" title="SuslinaZA , VarakinYY , VereshchaginNV . Clinical and epidemiological research - a promising area for the study of cerebrovascular pathology (first report) [Kliniko-epidemiologicheskiye issledovaniya – perspektivnoye napravleniye izucheniya tserebrovaskulyarnoy patologii (soobshcheniye pervoye)]. Annaly klinicheskoy i eksperimental’noy nevrologii [Annals of Clinical and Experimental Neurology]2009;3(3):4-11.">Suslina 2009</a>). Stroke survivors experience serious neurological disorders (loss of vision or speech, or both; paralysis; confusion), and in 30% to 66% of cases these are not restored six months after a stroke (<a href="./references#CD007026-bbs2-0055" title="FrenchB , ThomasLH , LeathleyMJ , SuttonCJ , McAdamJ , ForsterA , et al. Repetitive task training for improving functional ability after stroke. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD006073. [DOI: 10.1002/14651858.CD006073]">French 2007</a>; <a href="./references#CD007026-bbs2-0056" title="FrenchB , ThomasLH , CoupeJ , McMahonNE , ConnellL , HarrisonJ , et al. Repetitive task training for improving functional ability after stroke. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD006073. [DOI: 10.1002/14651858.CD006073.pub3]">French 2016</a>). In Russia, stroke is the primary cause of death and disability in adults: 32 cases per 100,000 population. Twenty‐five per cent to 30% of stroke survivors develop dementia by the end of one year. Stroke presents a huge financial burden for the health system (<a href="./references#CD007026-bbs2-0086" title="MartynchikSA , SokolovaOV . Medical and economic assessment and rationale for improving organization of inpatient care for cerebral stroke [Mediko-ekonomicheskaya otsenka i obosnovaniye sovershenstvovaniya organizatsionnykh form okazaniya statsionarnoy pomoshchi pri mozgovom insul’te]. Sotsial’nyye aspekty zdorov’ya naseleniya [Social Aspects of Population Health ]2013;30(2):e-pub without numbered pages. [vestnik.mednet.ru/content/view/473/30/lang,ru/]">Martynchik 2013</a>). The burden of stroke is projected to rise globally to 61 million DALYs in 2020 (<a href="./references#CD007026-bbs2-0127" title="World Health Organization. The Atlas of Heart Disease and Stroke. www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed November 2019).">WHO 2019a</a>). </p> </section> <section id="CD007026-sec-0015"> <h3 class="title" id="CD007026-sec-0015">Description of the intervention</h3> <p>Cerebrolysin is a mixture of low‐molecular‐weight peptides and amino acids derived from porcine brain, and has potential neuroprotective and neurotrophic properties. The manufacturer of Cerebrolysin promotes it for multiple neurological conditions, and it is widely used in the treatment of acute ischaemic stroke in Russia, China, and other Asian, Eastern‐European and post‐Soviet countries. Cortexin is a Russian‐made medicine, positioned by the manufacturer <a href="https://geropharm.ru/" target="_blank">Geropharm</a> as a Cerebrolysin‐like agent: a lyophilised extract of cerebral cortex of cattle (cows and pigs), a peptide mixture comprising polypeptides and amino acids, considered to be a bioregulator. It is used in Russia and the Commonwealth of Independent States (CIS) countries. </p> </section> <section id="CD007026-sec-0016"> <h3 class="title" id="CD007026-sec-0016">How the intervention might work</h3> <p>The term 'neuroprotection' is used to describe the putative effect of interventions protecting the brain from pathological damage. In ischaemic stroke, the concept of neuroprotection includes inhibition of pathological molecular events leading to calcium influx, activation of free radical reactions, and cell death. Knowledge of pathophysiology in acute ischaemic stroke stimulated the development of a number of potential neuroprotective agents. Many neuroprotective agents have proven to be efficacious in animal studies. Cerebrolysin is a mixture of low‐molecular‐weight peptides (80%) and free amino acids (20%) derived from porcine brain, with proposed neuroprotective and neurotrophic properties similar to naturally occurring growth factors such as nerve growth factor and brain‐derived neurotrophic factor (<a href="./references#CD007026-bbs2-0026" title="AlvarezXA , LombardiVR , CorzoL , PérezP , PichelV , LaredoM , et al. Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects. Journal of Neural Transmission2000;59:315-28.">Alvarez 2000</a>; <a href="./references#CD007026-bbs2-0054" title="FragosoY , DantasDC . Cerebrolysin for Alzheimer's disease. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003801. [DOI: 10.1002/14651858.CD003801]">Fragoso 2002</a>). In a study that identified 638 unique peptides in Cerebrolysin, none appeared to be related to any known trophic factor or trophic factor precursor, and it was suggested that the active peptides belong to proteins containing hidden functional peptide sequences (<a href="./references#CD007026-bbs2-0061" title="GevaertB , D'HondtM , BrackeN , YaoH , WyendaeleE , VissersJPC , et al. Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography – electrospray ionization ion trap and ultra high performance liquid chromatography – ion mobility – quadrupole time of flight mass spectrometry. Drug Testing and Analysis2015;7:835-42. [DOI: 10.1002/dta.1817]">Gevaert 2015</a>). Cortexin, similar to Cerebrolysin, is a mixture of 90% oligo‐ and short‐chain peptides and 10% amino acids (<a href="./references#CD007026-bbs2-0064" title="Gomazkov OA. Cortexin: molecular mechanisms and targets of neuroprotective activity [Кортексин: молекулярные механизмы и мишени нейропротективнойактивности]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2015;8:99-104. [DOI: 10.17116/jnevro20151158199-104]">Gomazkov 2015</a>). There is no clear understanding of the molecular mechanism of its action (<a href="./references#CD007026-bbs2-0070" title="GulyaevaNV . Molecular mechanisms of the actions of brain peptide-containing drugs: Cortexin. Neuroscience and Behavioral Physiology2019;49:1067-70. [DOI: 10.1007/s11055-019-00839-4]">Gulyaeva 2019</a>). </p> <p>Results of in vitro and animal studies of Cerebrolysin have traditionally been used to suggest its potential for treating acute ischaemic neuronal damage (<a href="./references#CD007026-bbs2-0087" title="MasliahE , Díez-TejedorE . The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of Today2012;48 Suppl A:3-24. [DOI: 10.1358/dot.2012.48(Suppl.A).1739716]">Masliah 2012</a>). For example, Cerebrolysin has been shown to be effective in tissue culture models of neuronal ischaemia, dose‐dependently increasing neuronal survival (<a href="./references#CD007026-bbs2-0113" title="SchauerE , WronskiR , PatockovaJ , MoesslerH , DopplerE , Hutter-PaierB , et al. Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. Journal of Neural Transmission2006;113(7):855-68.">Schauer 2006</a>). In brain slices it counteracts necrotic and apoptotic cell death induced by glutamate (<a href="./references#CD007026-bbs2-0105" title="RileyC , Hutter-PaierB , WindischM , DopplerE , MoesslerH , WronskiR . A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxication. Journal of Neural Transmission2006;113(1):103-10.">Riley 2006</a>). Cerebrolysin also demonstrates neuroprotective activity in rat models of haemorrhagic stroke (<a href="./references#CD007026-bbs2-0085" title="MakarenkoAN , KositsinNS , NazimovIV , SvinovMM , Goloborod'koEV , PasikovaNV . A comparative study of antistroke activity of the new drug &quot;cerebral&quot; and its fractions in rats [Сравнительное изучение антиинсультной активности церебрала и его отдельных субфракций в эксперименте]. Eksperimental'naia i Klinicheskaia Farmakologiia [Experimental and Clinical Pharmacology]2005;68(2):15-20.">Makarenko 2005</a>) and ischaemic stroke (<a href="./references#CD007026-bbs2-0134" title="ZhangCL , ChoppM , CuiYS , WangL , ZhangRL , ZhangL , et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. Journal of Neuroscience Research2010;88(15):3275-81.">Zhang 2010</a>), as well as in spinal cord trauma (<a href="./references#CD007026-bbs2-0112" title="SapronovNS , Bul'onVV , KuznetsovaNN , SelinaEN . The neuroprotector effect of a new taurine derivative on a model of compression spinal cord trauma in rats [Neyroprotektornyy effekt novogo proizvodnogo taurina pri kompressionnoy travme spinnogo mozga]. Eksperimental'naya i Klinicheskaya Farmakologiya [Experimental and Clinical Pharmacology]2005;68(6):45-8.">Sapronov 2005</a>). One randomised, double‐blind, placebo‐controlled trial showed no effect of Cerebrolysin in acute haemorrhagic stroke on chosen efficacy measures including the Barthel Index, Unified Neurological Stroke Scale, and Syndrome Short Test (<a href="./references#CD007026-bbs2-0028" title="BajenaruO , TiuC , MoesslerH , AntochiF , MuresanuD , PopescuBO , et al. Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke. Journal of Medicine and Life2010;3(2):137-43.">Bajenaru 2010</a>). </p> </section> <section id="CD007026-sec-0017"> <h3 class="title" id="CD007026-sec-0017">Why it is important to do this review</h3> <p>Despite the effectiveness of neuroprotective agents in animal models of stroke, the results of clinical trials of neuroprotective agents in humans have been disappointing (<a href="./references#CD007026-bbs2-0052" title="The European Ad Hoc Consensus Group. Neuroprotection as initial therapy in acute stroke. Third report of an ad hoc consensus group meeting. Cerebrovascular Diseases1998;8(1):59-72.">European Ad Hoc Consensus 1998</a>; <a href="./references#CD007026-bbs2-0062" title="GinsbergMD . Expanding the concept of neuroprotection for acute ischemic stroke: the pivotal roles of reperfusion and the collateral circulation. Progress in Neurobiology2016;145-6:46-77. [DOI: 10.1016/j.pneurobio.2016.09.002]">Ginsberg 2016</a>; <a href="./references#CD007026-bbs2-0063" title="GoenkaL , Uppugunduri SatyanarayanaCR , SSK , GeorgeM . Neuroprotective agents in acute ischemic stroke - a reality check. Biomedicine &amp; Pharmacotherapy2019;109:2539-47. [DOI: 10.1016/j.biopha.2018.11.041]">Goenka 2019</a>). Cochrane Reviews of the effects of individual neuroprotective agents and pharmacological groups confirm this (<a href="./references#CD007026-bbs2-0058" title="GandolfoC , SandercockP , ContiM . Lubeluzole for acute ischaemic stroke. Cochrane Database of Systematic Reviews2002, Issue 1. Art. No: CD001924. [DOI: 10.1002/14651858.CD001924]">Gandolfo 2002</a>; <a href="./references#CD007026-bbs2-0092" title="MuirKW , LeesKR . Excitatory amino acid antagonists for acute stroke. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD001244. [DOI: 10.1002/14651858.CD001244]">Muir 2003</a>; <a href="./references#CD007026-bbs2-0102" title="RicciS , CelaniMG , CantisaniTA , RighettiE . Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD000419. [DOI: 10.1002/14651858.CD000419.pub3]">Ricci 2012a</a>; <a href="./references#CD007026-bbs2-0120" title="BathPM , IddendenR , BathFJ , OrgogozoJM , Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD002087. [DOI: 10.1002/14651858.CD002087]">TISC 2001</a>). Yet, other means of neuroprotection are being sought. Cerebrolysin is well accepted by Russian, Eastern European, and Asian physicians, and is widely used in the treatment of acute ischaemic stroke and other neurological disorders (<a href="./references#CD007026-bbs2-0046" title="ChukanovaEI . The effect of Cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2005;105(1):42-5.">Chukanova 2005</a>; <a href="./references#CD007026-bbs2-0068" title="GromovaOA , Tret'iakovVE , MoshkovskiĭSA , GusevEI , NikonovAA , Val'kovaLA , et al. An oligopeptide membrane fraction of Cerebrolysin. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2006;106(7):68-70.">Gromova 2006</a>; <a href="./references#CD007026-bbs2-0094" title="OnishchenkoLS , GaikovaON , IanishevskiiSN . Changes in the focus of experimental ischemic stroke under the influence of neuroprotective drugs. Morfologiia [Morphology]2006;130(6):40-6.">Onishchenko 2006</a>). Research data from observational studies and clinical trials of Cerebrolysin in acute stroke or head injury, most of which have been performed in Russia and China, have accumulated (<a href="./references#CD007026-bbs2-0046" title="ChukanovaEI . The effect of Cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2005;105(1):42-5.">Chukanova 2005</a>; <a href="./references#CD007026-bbs2-0057" title="GafurovBG , AlikulovaNA . Clinical and pathogenetical peculiarities and treatment policy in ischemic stroke of elderly and old age. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;104 Suppl 11:44-6.">Gafurov 2004</a>; <a href="./references#CD007026-bbs2-0068" title="GromovaOA , Tret'iakovVE , MoshkovskiĭSA , GusevEI , NikonovAA , Val'kovaLA , et al. An oligopeptide membrane fraction of Cerebrolysin. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2006;106(7):68-70.">Gromova 2006</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>; <a href="./references#CD007026-bbs2-0130" title="WongGK , ZhuXL , PoonWS . Beneficial effect of Cerebrolysin on moderate and severe head injury patients: result of a cohort study. Acta Neurochirurgica Supplement2005;95:59-60. [DOI: 10.1007/3-211-32318-x_13]">Wong 2005</a>). </p> <p>As assessed in a Cochrane Review for vascular dementia, Cerebrolysin may have positive effects on cognitive function and global function in elderly people with mild to moderate dementia, but the review authors did not recommend it for routine use in vascular dementia owing to the limitations of the studies in the resulting review, small number of included trials, wide variety of treatment durations, short‐term follow‐up, and high risk of bias of the included studies (<a href="./references#CD007026-bbs2-0049" title="CuiS , ChenN , YangM , GuoJ , ZhouM , ZhuC . Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews2019, Issue 11. Art. No: CD008900. [DOI: 10.1002/14651858.CD008900.pub3]">Cui 2019</a>). Cerebrolysin has also been proposed as a treatment for people with Alzheimer's disease (<a href="./references#CD007026-bbs2-0054" title="FragosoY , DantasDC . Cerebrolysin for Alzheimer's disease. Cochrane Database of Systematic Reviews2002, Issue 3. Art. No: CD003801. [DOI: 10.1002/14651858.CD003801]">Fragoso 2002</a>). Trials of Cerebrolysin in acute haemorrhagic stroke have been assessed in a meta‐analysis (<a href="./references#CD007026-bbs2-0116" title="ShuLLS , San JoseCZ , PascoPP . The efficacy and safety of cerebrolysin in acute hemorrhagic stroke: a meta analysis. Cerebrovascular Diseases2012;34 Suppl 1:36.">Shu 2012</a>), which concluded on its safety and supported implementation of new trials for definitive efficacy assessment. </p> <p>Previous versions of this Cochrane Review did not find evidence of clinical benefit of Cerebrolysin for treating acute ischaemic stroke (<a href="./references#CD007026-bbs2-0137" title="ZiganshinaLE , AbakumovaT , KuchaevaA . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub2]">Ziganshina 2010a</a>; <a href="./references#CD007026-bbs2-0140" title="ZiganshinaLE , AbakumovaT . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub3]">Ziganshina 2015</a>; <a href="./references#CD007026-bbs2-0141" title="ZiganshinaLE , AbakumovaT , VernayL . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub4]">Ziganshina 2016</a>; <a href="./references#CD007026-bbs2-0142" title="ZiganshinaLE , AbakumovaT , VernayL . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub5]">Ziganshina 2017</a>), and provoked a number of published papers, particularly in Russian language academic media, in favour of using Cerebrolysin for treating acute ischaemic stroke, which we illustrate in the PRISMA flow diagram developed for the 2020 update (<a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>). <a href="./references#CD007026-bbs2-0142" title="ZiganshinaLE , AbakumovaT , VernayL . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub5]">Ziganshina 2017</a> created heated debate in the journal <i>Stroke</i> (<a href="./references#CD007026-bbs2-0037" title="BereczkiD . Hope dies last - evidence again fails to support a neuroprotectant Cerebrolysin for acute ischemic stroke. Stroke2017;48:2343-4. [DOI: 10.1161/STROKEAHA.117.018202]">Bereczki 2017</a>). However, the debate did not address the challenges of dealing with potential risk of bias in clinical trials, which in our view reflects an important contribution of Cochrane Reviews. </p> <p>The most recent update provided moderate‐certainty evidence of an increase in non‐fatal serious adverse events with Cerebrolysin use (<a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>). It is important to evaluate the data that have accumulated since then in order to provide better‐certainty evidence. </p> <p>Amongst the English language publications, there is a meta‐analysis of nine clinical trials (<a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a>), presenting a critique of the findings of the Cochrane Review (<a href="./references#CD007026-bbs2-0142" title="ZiganshinaLE , AbakumovaT , VernayL . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub5]">Ziganshina 2017</a>). We critically appraise <a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a> in the <a href="#CD007026-sec-0071">Agreements and disagreements with other studies or reviews</a> in the <a href="#CD007026-sec-0066">Discussion</a> section. The last update of this review, <a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>, received extensive comments from the manufacturer of Cerebrolysin, all of which are included in the Comments section with our detailed replies. The 2020 update, <a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>, was used to inform two joint guidelines from the European Stroke Organisation and the European Academy of Neurology on post‐stroke cognitive impairment (<a href="./references#CD007026-bbs2-0096" title="QuinnTJ , RichardE , TeuschlY , GattringerT , HafdiM , O'BrienJT , et al. European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. European Journal of Neurology2021;28(12):3883-920. [DOI: 10.1111/ene.15068]">Quinn 2021a</a>; <a href="./references#CD007026-bbs2-0097" title="QuinnTJ , RichardE , TeuschlY , GattringerT , HafdiM , O'BrienJT , et al. European Stroke Organisation and European Academy of Neurology joint guidelines on post-stroke cognitive impairment. European Stroke Journal2021;6(3):I-XXXVIII. [DOI: 10.1177/23969873211042192]">Quinn 2021b</a>). Both guidelines advise against Cerebrolysin use. </p> <p>This interest in and attention to the research question of our Cochrane Review, particularly in view of the debate around reliable evidence (<a href="./references#CD007026-bbs2-0078" title="HortonR . Offline: the gravy train of systematic reviews. Lancet2019;394(16):1790. [DOI: 10.1016/S0140-6736(19)32766-7]">Horton 2019</a>), encouraged us to update the review once again and revisit the question of reliability of evidence. </p> <p>This review update is particularly pertinent in view of the continuous presence of Cerebrolysin and the Cerebrolysin‐like agent, Cortexin, on the national Essential Medicines List of the Russian Federation (<a href="./references#CD007026-bbs2-0065" title="Government of the Russian Federation. Essential Medicines List for 2019 [Правительство российской федерации]. static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf (accessed prior to 23 June 2020).">GovRu 2019</a>; <a href="./references#CD007026-bbs2-0066" title="Government of the Russian Federation. Corrections to Essential Medicines List for 2019 [Правительство Российской Федерации]. static.government.ru/media/files/gGR64GGr0trcTnxAVXA0y4KwW9iUHGtI.pdf 23 December 2021 (accessed May 2023).">GovRu 2022</a>). Both peptide mixtures of the cattle cerebral cortex are recommended for use in acute ischaemic stroke by the national clinical practice guidelines of Russia (<a href="./references#CD007026-bbs2-0090" title="Ministry of Healthcare of the Russian Federation. Cliniсal guidelines. Ischemic stroke and transient ischemic attack in adults [Клинические рекомендации. Ишемический инсульт и транзиторная ишемическая атака у взрослых]. https://cr.minzdrav.gov.ru/schema/171_2 2021 (accessed October 2022).">MinHealthRu 2021</a>). Cerebrolysin is also listed on the national Essential Medicines Lists of Slovakia, Romania, Vietnam, Uganda, and the Syrian Arab Republic (<a href="./references#CD007026-bbs2-0128" title="National Essential Medicines Lists. www.who.int/selection_medicines/country_lists (accessed November 2019).">WHO 2019b</a>; <a href="./references#CD007026-bbs2-0129" title="WHO Global Essential Medicine Lists. https://global.essentialmeds.org/dashboard/medicines (accessed October 2022).">WHO 2022</a>), with uses including acute ischaemic stroke. </p> <p>In this review update we followed all the methodological approaches refined in the previous update, and once again re‐assessed our judgements of the risk of bias for uniformity of judgements across all included studies. </p> <p>Studies reporting on our outcome measures was not an inclusion criterion for this review; changes in the reporting of outcomes in our data synthesis depended on data reported by the authors of eligible included trials in their trial reports. </p> <p>The aim of this update was to establish whether the new search and inclusion of data from a newly identified trial would affect the conclusions of the former version of the review, in view of the thorough re‐assessment of the risk of bias in the included studies through identification, examination, and evaluation of study protocols, and careful data extraction. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007026-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007026-sec-0018"></div> <p>To assess the benefits and harms of Cerebrolysin or Cerebrolysin‐like agents for treating acute ischaemic stroke. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007026-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007026-sec-0019"></div> <section id="CD007026-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007026-sec-0021"> <h4 class="title">Types of studies</h4> <p>We included all published randomised controlled trials (RCTs) comparing Cerebrolysin or Cerebrolysin‐like agents with placebo or no treatment in people with acute ischaemic stroke. We excluded uncontrolled studies, as well as quasi‐RCTs where allocation to treatment or control was not concealed (e.g. allocation by alteration, open random number list, date of birth, day of the week, or hospital number). </p> </section> <section id="CD007026-sec-0022"> <h4 class="title">Types of participants</h4> <p>People with acute ischaemic stroke, confirmed by neuroimaging, irrespective of age, sex, or social status, whose symptom onset was less than 48 hours previously. Stroke symptoms include: sudden weakness or numbness of the face, arm, or leg, often unilateral; confusion; difficulties in speaking or seeing with one or both eyes; difficulties walking; loss of balance or co‐ordination; severe no‐cause headache; fainting or loss of consciousness. Confirmation of stroke diagnosis with neuroimaging was not an inclusion criterion for the earlier versions of this review. However, confirmation of stroke diagnosis with neuroimaging is now mandatory, as we stated in the last update. </p> <p>The condition of interest in this review is acute ischaemic stroke, as defined above, therefore methods to deal with studies that include only a subset of eligible participants are not required, as such studies would not be conducted. </p> </section> <section id="CD007026-sec-0023"> <h4 class="title">Types of interventions</h4> <p>We compared Cerebrolysin or Cerebrolysin‐like agents added to standard treatment against either placebo or no treatment added to standard treatment. </p> <p>Standard treatment is not defined precisely and differs between studies. Study medication must have been started within 48 hours of onset of stroke and continued for any period of time. </p> <p>We planned to add a separate analysis for the comparison 'Cerebrolysin versus other neuroprotective agents (peptide mixtures)', but the available studies did not permit this. We identified in the searches for this update a single eligible trial of a newer peptide mixture, which we have termed a 'Cerebrolysin‐like agent', a Russian‐produced medicine, Cortexin. The trial provided data for Cortexin versus placebo only. We combined outcome data for Cerebrolysin with data for the newer peptide mixture, Cortexin. </p> </section> <section id="CD007026-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>We used one primary outcome and six secondary outcomes, with special attention to adverse events and effects. </p> <p>We were interested in outcomes measured up to 90 days.</p> <section id="CD007026-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007026-list-0001"> <li> <p>All‐cause death, to be measured as the number of people who died from the start of tested treatment to the end of the follow‐up period. </p> </li> </ul> </p> </section> <section id="CD007026-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p>Poor functional outcome, defined as death or dependence at the end of the follow‐up period: various scales, such as the National Institutes of Health Stroke Scale (NIHSS), the modified Rankin Scale (mRS), and the Barthel Scale/Index (BI) can be used to evaluate impairment brought about by stroke. The mRS is commonly used and is a scale from 0 to 6, with 0 being no symptoms; 1, no significant disability; 2, slight disability; 3, moderate disability; 4, moderate to severe disability; 5, severe disability; and 6, death. </p> <p> <ul id="CD007026-list-0002"> <li> <p>Early death (within two weeks of stroke onset).</p> </li> <li> <p>Quality of life, if assessed in the included studies.</p> </li> <li> <p>Time to restoration of capacity for work, either as a time‐to‐event outcome (e.g. analysed as a hazard ratio) or as a continuous outcome, depending on study data. </p> </li> <li> <p>Cause of death.</p> </li> <li> <p>Non‐death attrition. After identifying and evaluating available trial registration protocols, we added this outcome to the previous update (<a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>) as a measure not only of attrition per se, but also as a grey zone in the presentation of trial populations, allowing us to characterise attrition and reporting bias better. </p> </li> </ul> </p> <section id="CD007026-sec-0027"> <h6 class="title">Adverse events and effects</h6> <p>A serious adverse event (SAE), as defined according to the International Council for Harmonisation guideline, is "any untoward medical occurrence that, at any dose, results in death, is life‐threatening, requires inpatient hospitalisation or results in prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a medically important event or reaction" (<a href="./references#CD007026-bbs2-0079" title="ICH Expert Working Group. ICH Harmonised tripartite guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D. database.ich.org/sites/default/files/E2D_Guideline.pdf 12 November 2003 (accessed May 2023).">ICH 2003</a>). We confirmed the definition of SAE used by researchers and the numbers of people with SAEs in the <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> trial through correspondence with the manufacturer of Cerebrolysin and the lead author of this trial, and we extracted data from the <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> trial report that used Medical Dictionary for Regulatory Activities (MedDRA) coded SOC (System Organ Class) and Preferred Term (PT) (<a href="./references#CD007026-bbs2-0088" title="MedDRA Maintenance and Support Services Organization. Introductory Guide to MedDRA Version 14.0. www.meddra.org/how-to-use/support-documentation (accessed prior to 23 June 2020).">MedDRA 2011</a>), developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (<a href="./references#CD007026-bbs2-0079" title="ICH Expert Working Group. ICH Harmonised tripartite guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D. database.ich.org/sites/default/files/E2D_Guideline.pdf 12 November 2003 (accessed May 2023).">ICH 2003</a>). </p> <p>We used the following outcomes for SAEs:</p> <p> <ul id="CD007026-list-0003"> <li> <p>Total number of people with SAEs.</p> </li> <li> <p>Total number of people with fatal SAEs.</p> </li> <li> <p>Total number of people with non‐fatal SAEs.</p> </li> <li> <p>Total number of people with adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD007026-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials regardless of language or publication status, and arranged for the translation of relevant papers where necessary. </p> <section id="CD007026-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases:</p> <p> <ul id="CD007026-list-0004"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL 2022, Issue 5) (last searched 9 May 2022; <a href="./appendices#CD007026-sec-0078">Appendix 1</a>); </p> </li> <li> <p>MEDLINE Ovid (from 1946; last searched 9 May 2022; <a href="./appendices#CD007026-sec-0079">Appendix 2</a>); </p> </li> <li> <p>Embase Ovid (from 1980; last searched 9 May 2022; <a href="./appendices#CD007026-sec-0080">Appendix 3</a>); </p> </li> <li> <p>Science Citation Index Expanded Indexes and Conference Proceedings Citation Index ‐ Science – Web of Science Core Collection (last searched 9 May 2022; <a href="./appendices#CD007026-sec-0081">Appendix 4</a>); </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Sciences Literature database) (1982 to 7 June 2022; <a href="./appendices#CD007026-sec-0082">Appendix 5</a>); </p> </li> <li> <p>OpenGrey (System for Information on Grey Literature in Europe; <a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu</a>; 1980 to 24 October 2019; <a href="./appendices#CD007026-sec-0083">Appendix 6</a>, used in the previous version of the review); </p> </li> <li> <p>the following Russian Databases: e‐library (<a href="http://elibrary.ru" target="_blank">elibrary.ru</a>; 1998 to 7 June 2022) and EastView (<a href="http://online.ebiblioteka.ru/index.jsp" target="_blank">online.ebiblioteka.ru/index.jsp</a>; 2006 to 7 June 2022; <a href="./appendices#CD007026-sec-0084">Appendix 7</a>). </p> </li> </ul> </p> <p>The Cochrane Stroke Information Specialist developed the search strategies for CENTRAL, MEDLINE, Embase, Web of Science indexes, and trial registers. We then adapted the MEDLINE strategy for the additional Russian language databases. </p> </section> <section id="CD007026-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We also searched the following ongoing trials and research registers:</p> <p> <ul id="CD007026-list-0005"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (last searched 9 May 2022; <a href="./appendices#CD007026-sec-0085">Appendix 8</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) (last searched 9 May 2022; <a href="./appendices#CD007026-sec-0086">Appendix 9</a>); </p> </li> <li> <p>Russian State Register of Approved Medicines (<a href="https://grls.rosminzdrav.ru/" target="_blank">grls.rosminzdrav.ru</a>) (last searched 8 June 2022). </p> </li> </ul> </p> <p>In an effort to identify further published, unpublished, and ongoing trials and to obtain additional trial information, we checked the reference lists of all trials identified by the above methods, and searched the following neurology conference proceedings held in Russia: <i>Chelovek i Lekarstvo</i> [Man and Medicine] (2019 to 2022), <i>National'niy congress cardiologov</i> [The National Congress of Cardiology] (2019 to 2022), <i>XI Vserossiyskiy s'ezd nevrologov i IV kongress Natsional'noy assotsiatsii po bor'be s insultom</i> [XI All‐Russian Congress of Neurologists and IV Congress of the National Stroke Association] (2019), <i>Mezhdunarodniy kongress "Neiroreabilitatsiya‐16"</i> [International Congress "Neurorehabilitation‐16"] (2019‐2022). </p> <p>For this update we did not contact the pharmaceutical company EVER Neuro Pharma GmbH, the manufacturer of Cerebrolysin, because we did not identify any new trials of Cerebrolysin. We did not contact the pharmaceutical company Geropharm, the manufacturer of Cortexin, because we included only one trial, which had duplicate publications, and in neither of them did the authors refer in any form to the manufacturer of Cortexin. </p> <p>We cross‐referenced all studies included in this review with Retraction Watch (both the <a href="./references#CD007026-bbs2-0099" title="MarcusA , OranskyI . Retraction Watch. retractionwatch.com (accessed 8 June 2022).">Retraction Watch</a> site and the <a href="./references#CD007026-bbs2-0100" title="MarcusA , OranskyI . Retraction Watch Database. retractiondatabase.org/RetractionSearch.aspx? (accessed 8 June 2022).">Retraction Watch Database</a>); last searched June 2022; <a href="./appendices#CD007026-sec-0087">Appendix 10</a>). </p> </section> </section> <section id="CD007026-sec-0031"> <h3 class="title" id="CD007026-sec-0031">Data collection and analysis</h3> <section id="CD007026-sec-0032"> <h4 class="title">Selection of studies</h4> <p>All review authors (LEZ, DN, KI and TRA) independently examined the titles and abstracts of records from the electronic searches and excluded those studies that were obviously irrelevant. We used the results of our work in <a href="./references#CD007026-bbs2-0048" title="Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org (accessed May 2023).">Covidence</a> for the previous version of the review, and added the newly identified RCT (<a href="#CD007026-fig-0001">Figure 1</a>). We obtained the full texts of all eligible papers, and the same review authors independently selected studies for inclusion based on the predetermined inclusion criteria refined for the last update. Any disagreements were resolved through discussion. We excluded studies that did not meet the inclusion criteria, providing reasons for their exclusion in the <a href="./references#CD007026-sec-0137" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD007026-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD007026-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD007026-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>All review authors (LEZ, DN, KI, and TRA) independently extracted data on the methods of the studies, participants, interventions, and outcomes. We resolved any differences in the extracted data by referring to the original articles and through discussion. We extracted data to allow an intention‐to‐treat (ITT) analysis (including all participants in the groups to which they had been randomly allocated). We used these data for the outcome 'all‐cause death' in the worst‐/best‐case analyses we used as sensitivity analyses. We presented the data in the <a href="./references#CD007026-sec-0136" title="">Characteristics of included studies</a> table, generated by Covidence. For all included trials we calculated the percentage loss to follow‐up and presented this information in the risk of bias tables. </p> <p>For binary outcomes, we extracted the number of participants with the event in each group. For continuous outcomes, we planned to use arithmetic means and standard deviations for each group. </p> </section> <section id="CD007026-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (DN, KI and LEZ) independently evaluated the methodological quality of studies with regard to the generation of allocation sequence, allocation concealment, blinding, loss to follow‐up, and other risk of bias using the Cochrane risk of bias assessment tool (<a href="./references#CD007026-bbs2-0076" title="HigginsJPT , AltmanDG , SterneJAC , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org (accessed May 2023).">Higgins 2011</a>). </p> <p>We followed the Cochrane guidance to assess whether adequate steps had been taken to reduce the risk of bias across seven domains: generation of allocation sequence; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data (attrition bias); selective outcome reporting; and other sources of bias. We assigned judgements of 'low', 'high', or 'unclear' risk of bias for these domains. We considered loss to follow‐up to be acceptable (low risk of bias) if it was less than 10%. We thoroughly re‐assessed risk of bias for all included studies across all domains to ensure uniformity of our judgements. </p> <p>In this update we used the same approach for risk of bias assessment that was re‐evaluated for the previous update. We added consideration of public availability of study protocols and reported outcomes to the selective outcome reporting judgement through identification, examination, and evaluation of study protocols. </p> <p>For the assessment of other sources of bias, we evaluated how study authors described funding sources for their trials and how conflict of interest statements were presented, if presented at all. We judged the risk of bias to be high in cases of clear sponsorship by the manufacturers of Cerebrolysin or Cortexin, involvement of the manufacturer with trial planning and design, sequence generation, medication provision, statistical procedures, blinding of personnel and outcome assessors, and involvement in reporting, as well as in cases of declared relationship of study authors to the manufacturer of Cerebrolysin. Where there was no mention of funding sources and there were no conflict of interest statements, we judged the risk of bias to be unclear. </p> <p>We resolved any disagreements arising at any stage by discussion.</p> <p>We planned to use funnel plots to examine asymmetry, which may be caused by publication bias or heterogeneity. </p> </section> <section id="CD007026-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>We presented dichotomous data and combined them using risk ratios (RRs). We showed RRs accompanied by 95% confidence intervals (CIs). We planned to present continuous outcomes, if identified, as means accompanied by standard deviations (SDs) or as the standardised mean difference (SMD). </p> </section> <section id="CD007026-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>We only included studies that randomised individual participants. We did not identify in the searches any cluster‐randomised or cross‐over trials, and we did not have multiple time points. </p> <p>For studies with multiple groups we split the 'shared' group into two or more groups with smaller sample sizes, and included two or more (reasonably independent) comparisons. </p> <p>Non‐standard study designs such as cluster‐RCTs and cross‐over trials would be inapplicable owing to the nature of the condition of interest of this review. Acute ischaemic stroke is an emergency condition and the eligibility criteria for this review specify participants with stroke symptom onset less than 48 hours before starting study medicines. </p> </section> <section id="CD007026-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>Where data from the trial reports were insufficient, unclear, or missing, we attempted to contact the trial authors for additional information. We aimed to carry out an intention‐to‐treat (ITT) analysis, but as there were missing data we did a complete case analysis (i.e. including all patients with a measured outcome as per trial authors). The complete case analysis does not make an assumption about the outcome of missing patients. </p> <p>We explored the potential effects of missing data through a series of sensitivity analyses (<a href="#CD007026-tbl-0002">Table 1</a>). As a sensitivity analysis, we did a best‐/worst‐case analysis. The best‐case analysis assumed missing patients had a positive outcome (survived acute ischaemic stroke); the worst‐case analysis assumed they had a negative outcome (died). We conducted a sensitivity analysis that aimed to restore the integrity of the randomisation process (as is usual in trial analysis) and test the robustness of the results to this methodology. For a summary of the methodology and sensitivity analysis see <a href="#CD007026-tbl-0002">Table 1</a>. </p> <div class="table" id="CD007026-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome all‐cause death and sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Nominator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Denominator</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary analysis</p> <p>(Intention‐to‐treat, best‐case)</p> <p>Sensitivity analysis 1 ‐ best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity analysis 2 ‐ worst‐case<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included as deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed case analysis (as per trial authors)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>"Excluded" means removed from the calculation. </p> <p><sup>b</sup>To re‐classify missing participants (missing data, including losses to follow‐up) as treatment failures. For negative outcomes (death) this represents a true worst‐case scenario. </p> </div> </div> </section> <section id="CD007026-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested for heterogeneity of effect sizes between studies by inspecting the forest plots and using the I<sup>2</sup> statistic (<a href="./references#CD007026-bbs2-0075" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), considering a value of 30% to 60% as denoting moderate levels of heterogeneity (<a href="./references#CD007026-bbs2-0050" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Deeks 2011</a>). If there was clinical heterogeneity, we planned to explore it in subgroup analysis if the amount of data permitted or to describe results narratively rather than pooling heterogeneous data. </p> </section> <section id="CD007026-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>If there was a sufficient number of studies (10 or more), we planned to use funnel plots to examine asymmetry that may have been caused by publication bias or heterogeneity. </p> <p>We compared the outcomes predefined in study protocols with those reported in the published manuscripts to detect potential selective reporting. </p> </section> <section id="CD007026-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We used the ITT principle for data synthesis. We used <a href="https://revman.cochrane.org/" target="_blank">RevMan Web</a> to analyse the data. We used the RR as the measure of effect for binary outcomes, and we used a fixed‐effect model for pooling the data in cases of no or a low level of heterogeneity. </p> <p>Where we detected heterogeneity (forest plot inspection and an I<sup>2</sup> statistic &gt; 30%), and it was still appropriate to pool the data, we used the random‐effects model. </p> <p>We used and presented 95% CIs for the RRs of all studied outcomes.</p> </section> <section id="CD007026-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated potential sources of heterogeneity for all outcomes using the following criteria for subgroups. </p> <p> <ul id="CD007026-list-0006"> <li> <p>Cerebrolysin or Cortexin dose.</p> </li> <li> <p>Length of treatment.</p> </li> </ul> </p> <p>We identified the following subgroups by Cerebrolysin dose and the length of treatment.</p> <p> <ul id="CD007026-list-0007"> <li> <p>30 mL for 10 days: cumulative dose 300 mL over 10 days.</p> </li> <li> <p>50 mL for 21 days: cumulative dose 1050 mL over 21 days.</p> </li> <li> <p>10 mL and 50 mL for 10 days: cumulative dose 100 mL and 500 mL over 10 days.</p> </li> </ul> </p> <p>We identified the following subgroups by Cortexin dose and the length of treatment.</p> <p> <ul id="CD007026-list-0008"> <li> <p>20 mg for 10 days, 10 days rest, then 20 mg for 10 days: cumulative dose 400 mg over 20 days (200 mg over 10 days ‐ rest ‐ 200 mg over 10 days). </p> </li> <li> <p>20 mg for 10 days, 10 days rest, then placebo for 10 days: cumulative dose 200 mg over 10 days. </p> </li> </ul> </p> </section> <section id="CD007026-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis to test the robustness of the results for the outcome all‐cause death. We explored the effect of missing data by carrying out a best‐/worst‐case analysis (<a href="#CD007026-tbl-0002">Table 1</a>). We investigated the effect of methodological study quality ('low', 'high', or 'unclear' risk of bias) by comparing the results of studies with low and unclear risk of bias with no losses to follow‐up (no attrition) to the results of studies with high risk of bias for selective outcome reporting (attrition bias). We compared the results obtained with the use of either a fixed‐effect or random‐effects model to test the robustness of the results. </p> </section> <section id="CD007026-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to interpret findings (<a href="./references#CD007026-bbs2-0114" title="SchunemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011</a>). We employed <a href="./references#CD007026-bbs2-0067" title="GRADEpro GDT. Version accessed prior to 27 June 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a>, and imported data from Review Manager 5 to create <a href="./full#CD007026-tbl-0001">summary of findings Table 1</a> for the following outcomes: the primary outcome of all‐cause death at the end of the follow‐up period; the total number of people with SAEs at the end of the follow‐up period, comprising fatal and non‐fatal SAEs, and a subgroup by Cerebrolysin dose and length of treatment, at the end of the follow‐up period (follow‐up period in the included studies varied from 28 days (four weeks) to 90 days); the total number of people with adverse events at the end of the follow‐up period; non‐death attrition; death or dependence at the end of the follow‐up period; early death (within two weeks of stroke onset); and quality of life (<a href="./references#CD007026-bbs2-0101" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p><a href="./full#CD007026-tbl-0001">summary of findings Table 1</a> includes information on the overall certainty of the evidence from the trials and information of importance for healthcare decision‐making. The GRADE approach determines the certainty of the evidence based on an evaluation of eight criteria (risk of bias, inconsistency, indirectness, imprecision, publication bias, effect size, presence of plausible confounding that will change effect, and dose‐response gradient). We used the criteria of risk of bias, inconsistency, indirectness, and imprecision to guide our conclusions and recommendations. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007026-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007026-sec-0044"></div> <section id="CD007026-sec-0045"> <h3 class="title">Description of studies</h3> <p>We report here on seven trials, which met the inclusion criteria, and how we identified these trials. </p> <section id="CD007026-sec-0046"> <h4 class="title">Results of the search</h4> <p>In the new searches we identified:</p> <p> <ul id="CD007026-list-0009"> <li> <p>204 records through database and trial registration platform searches, out of which 172 were left after duplicate removal; </p> </li> <li> <p>5821 records through Russian database searches (two duplicates were removed);</p> </li> <li> <p>nothing through our search of LILACS;</p> </li> <li> <p>nothing through Retraction Watch.</p> </li> </ul> </p> <p>The OpenGrey database was not available for the current search.</p> <p>After duplicate removal, we screened 5991 records and excluded 5976 as irrelevant.</p> <p>We assessed 15 records for eligibility (six full‐text articles, eight trial protocols, and one abstract). </p> <p>We excluded (with reasons) seven studies, which were presented in nine publications (six full‐text articles, three trial protocols), which we grouped in the <a href="#CD007026-sec-0048">Excluded studies</a> section. Reasons for the exclusion of studies are shown in <a href="./references#CD007026-sec-0137" title="">Characteristics of excluded studies</a>. </p> <p>Among the remaining six records, five studies were included in the list of ongoing trials. </p> <p>We included one new study. Thus, seven studies in total are included in the qualitative synthesis and six studies are included in the quantitative synthesis. </p> <p>For details, see <a href="./references#CD007026-sec-0136" title="">Characteristics of included studies</a> and <a href="./references#CD007026-sec-0138" title="">Characteristics of ongoing studies</a>. </p> <p>The results of the search are illustrated in the study flow diagram (<a href="#CD007026-fig-0001">Figure 1</a>). We designed an additional table for ongoing trials identified through clinical trials registries searches (<a href="#CD007026-tbl-0003">Table 2</a>). This demonstrates the intensity of clinical research in the field of potential use of peptide mixtures in people with acute ischaemic stroke, despite the fact that we advocate for no more trials of Cerebrolysin or Cerebrolysin‐like agents as it is unethical for patients to be recruited into a study without potential benefit, as found in the previous update of this review (<a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>). </p> <div class="table" id="CD007026-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ongoing studies</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records identified through database searching (ClinicalTrials.gov and WHO ICTRP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records identified through other sources, namely Russian trial registry (GRLS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duplicates removed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records excluded as irrelevant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial records assessed for eligibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial records excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in the list of ongoing studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in the list of ongoing studies in previous version of review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of studies included in the list of ongoing studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD007026-sec-0047"> <h4 class="title">Included studies</h4> <p>Seven trials met the published inclusion criteria.</p> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a> was performed in the Islamic Republic of Iran. The trial compared Cerebrolysin with placebo (normal saline) in 46 people (23 participants in each group) with acute ischaemic stroke confirmed by computed tomography (CT) scan or magnetic resonance imaging (MRI), or both. Cerebrolysin was started within 24 hours of stroke onset and continued for 10 days as a once‐daily intravenous infusion of 30 mL in addition to standard treatment of 100 mg of aspirin daily. The average age of trial participants was 60 years. There were no significant differences between the two groups in terms of baseline characteristics. The duration of follow‐up was 90 days; one participant in the Cerebrolysin group and two participants in the placebo group died within 30 days of trial initiation. The causes of death were not reported; these three people were excluded from the final analyses. The study protocol is not publicly available, and there is no mention of a study protocol in the text of the published trial report. The study authors reported the results of the trial in two publications (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>). </p> <p><a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> was a multicentre, placebo‐controlled trial performed in four countries: China, Hong Kong, South Korea, and Myanmar. The trial compared Cerebrolysin with placebo added to standard baseline therapy in 1070 people with acute ischaemic stroke confirmed with CT or MRI results compatible with a clinical diagnosis of acute hemispheric stroke (529 participants in the Cerebrolysin group and 541 participants in the control group). Cerebrolysin was started within 12 hours of stroke onset and continued for 10 days as a once‐daily intravenous infusion of 30 mL diluted in saline (total of 100 mL) in addition to standard treatment of 100 mg of aspirin daily. Placebo was 100 mL saline as a daily intravenous infusion for 10 days starting within 12 hours of stroke onset. The average age of the trial participants was 65 years. The duration of follow‐up was 90 days; 162 participants were lost to follow‐up (15%). There were differences between the two groups in terms of baseline prognostic variables, having more people with chronic diseases in the placebo group than in the Cerebrolysin group, 293 versus 251 (55% versus 46% of randomised participants). There were more people with diabetes, 117 (21.7%) versus 108 (20.5%); arrhythmia, 90 (16.7%) versus 71 (13.5%); and coronary heart disease, 86 (16.0%) versus 72 (13.7%) in the placebo group compared to the Cerebrolysin group. The trial was supported by the manufacturer of Cerebrolysin, EVER Neuro Pharma GmbH. The study authors reported the results of the trial in five publications (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> with the protocol registered at ClinicalTrials.gov (NCT00868283) and published as a separate paper (<a href="./references#CD007026-bbs2-0077" title="HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12.">Hong 2009</a>), both retrospectively). </p> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> was a multicentre, placebo‐controlled trial performed in five countries: Austria, Croatia, the Czech Republic, Slovakia, and Slovenia. The trial compared Cerebrolysin with placebo in 119 people (60 in the Cerebrolysin group and 59 in the control group) with acute hemispheric ischaemic stroke after exclusion of brain haemorrhage by CT. Cerebrolysin was started within two hours of stroke onset and continued for 10 consecutive days as a once‐daily intravenous infusion of 30 mL mixed with 70 mL of normal saline (total volume 100 mL over a time period of 30 minutes), starting immediately one hour after thrombolytic treatment (alteplase). The placebo consisted of 100 mL normal saline. The average age of the trial participants was 66 years. There were no significant differences between treatment groups in terms of baseline prognostic variables. The duration of follow‐up was 90 days, and 19 participants of 119 (16%) were lost to follow‐up. The study authors did not report any information on funding sources of the trial, including provision of Cerebrolysin. The statistician of the study was contracted by EVER Neuro Pharma GmbH, the manufacturer of Cerebrolysin. The study authors reported the results of the trial in one publication (<a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>), with the protocol registered at ClinicalTrials.gov retrospectively (NCT00840671). </p> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> was a randomised, multicentre, prospective, double‐blind, placebo‐controlled trial performed in Russia. The study compared Cortexin with placebo in 272 people with acute ischaemic stroke in the basin of the internal carotid artery, after exclusion of brain haemorrhage by CT or MRI. Cortexin was started within 24 hours of stroke onset. Patients were randomised into three groups. The first group (136 participants) was treated with Cortexin at a dose of 10 mg two times a day (morning and afternoon) for 10 days; after a 10‐day break the same course of treatment was repeated. The authors did not provide any information on the standard baseline therapy. The second group (72 participants) received Cortexin during the first 10 days of the onset of stroke at a dose of 10 mg two times a day (morning and afternoon), then placebo for 10 days after a 10‐day break. The third group (64 participants) received placebo in two 10‐day courses with a 10‐day break between them. The average age of the trial participants was 62 years. The authors reported a lower incidence of hypercholesterolaemia in the Cortexin + Cortexin group compared to patients in the Cortexin + placebo group. Other baseline characteristics were not significantly different between the groups. The median NIH score at admission in all groups was 6 (the mean NIH score was 7.03 in the Cortexin group, 7.68 in the Cortexin + placebo group, and 7.94 in the placebo + placebo group), which is lower than in most of the included studies of Cerebrolysin (<a href="#CD007026-tbl-0004">Table 3</a>). The duration of follow‐up was 60 to 70 days (two months). The authors reported no losses to follow‐up. There were seven deaths in the Cortexin groups (4/136 and 3/72), no deaths in the placebo group and no other losses to follow‐up (non‐death attrition). The authors did not provide any information on funding sources for the trial or a conflict of interest statement. The study authors reported the results of the trial in two publications (<a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>). We did not find a trial protocol, either published or registered with any of trial registration databases. The study contributed data only on three outcomes of interest in this review: all‐cause death, total number of people with adverse events, and non‐death attrition. </p> <div class="table" id="CD007026-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NIHSS score at admission</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline score at admission</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin ‐ 14 (13 to 15)</p> <p>Placebo ‐ 14 (12 to 16)</p> <p><i>Median (IQR)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin ‐ 9 (6 to 33)</p> <p>Placebo ‐ 9 (6 to 26)</p> <p><i>Median (range)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin 12.3 (5.39)</p> <p>Placebo 11.0 (5.44)</p> <p><i>Mean (SD)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No info on NIHSS, the Canadian Neurological Scale (CNS) and the Glasgow Coma Scale (GCS) were measured </p> <p>Cerebrolysin ‐ CNS 6.88 (0.09); GCS 14.1 (0.20)</p> <p>Placebo ‐ CNS 6.68 (0.14); 14.4 (0.16)</p> <p><i>Mean (SEM)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin 11.2 ± 4.7</p> <p>Placebo 12.2 ± 2.8</p> <p><i>Mean (±)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cortexin + Cortexin 7.03 (3.63); 6.0</p> <p>Cortexin + placebo 7.68 (4.94); 6.0</p> <p>Placebo + placebo 7.94 (4.58); 6.0</p> <p><i>Mean (SD); median</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin 10.60 (4.74)</p> <p>Placebo 10.20 (3.72)</p> <p><i>Mean (SD)</i> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IQR: interquartile range<br/>NIHSS: National Institutes of Health Stroke Scale<br/>SD: standard deviation<br/>SEM: standard error of the mean </p> </div> </div> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> was a multicentre, placebo‐controlled trial conducted in Austria, the Czech Republic, and Hungary. The trial compared Cerebrolysin with placebo (100 mL normal saline) added to standard baseline therapy in 146 people with acute ischaemic stroke with clinical symptoms of the middle cerebral artery area after exclusion of brain haemorrhage by CT. Cerebrolysin (50 mL mixed with 50 mL of normal saline) and placebo were started within 24 hours of stroke onset and continued for 21 days as a once‐daily intravenous infusion over a period of 20 minutes. The same basic therapy was used in the treatment group and the control group (pentoxifylline and acetylsalicylic acid): Cerebrolysin plus basic therapy, 78 participants and placebo plus basic therapy, 68 participants. The average age of the trial participants was 65 years. The duration of follow‐up was 90 days. Twenty‐five participants (17%) were lost to follow‐up, nine in the treatment group and 16 in the control group. There were no significant differences between the two groups in terms of baseline characteristics. The trial was supported by the manufacturer of Cerebrolysin, EVER Neuro Pharma GmbH, who also provided the study centres with Cerebrolysin. The study authors reported the results of the trial in three publications (<a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>). </p> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> was performed in Russia. The trial compared Cerebrolysin with placebo added to standard baseline therapy in 36 people with acute ischaemic stroke in the territory of the internal carotid artery, confirmed by CT or MRI. Cerebrolysin was started within 12 hours of stroke onset and was continued for 10 days as a once‐daily intravenous infusion of either 10 mL or 50 mL. There were three groups, 12 participants in each, treated with 10 mL Cerebrolysin, 50 mL Cerebrolysin, or placebo. Standard baseline therapy consisted of aspirin 100 mg per day, haemodilution, pentoxifylline, and heparin (when needed). There were no significant differences in baseline characteristics between groups. The average age of the trial participants was 69 years. The duration of follow‐up was 30 days, and there were no losses to follow‐up. No information on funding sources for the trial and no conflict of interest statements were provided. The study authors reported the results of the trial in three publications (<a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). </p> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> was performed in China. The trial compared Cerebrolysin with placebo and another neuroprotective agent (DL‐3‐n‐butylphthalide; NBP) in 60 people with acute ischaemic stroke, confirmed by CT or MRI (20 participants each). There were no significant differences in baseline characteristics between the Cerebrolysin and placebo groups. Cerebrolysin was administered for 10 days as a once‐daily intravenous infusion of 30 mL mixed with 70 mL of normal saline; the infusions lasted for 50 to 70 minutes. Participants in the control group received intravenous infusions of 100 mL of normal saline, whilst the Cerebrolysin group received an intravenous infusion of 100 mL of 25 mg NBP in normal saline, twice daily for 10 days starting within 12 hours after stroke onset. Standard baseline therapy consisted of antithrombotics, hypoglycaemics, antilipaemic agents, antihypertensives, and dehydration, according to local current guidelines for the management of ischaemic stroke in neurological intensive care units, and 100 mg aspirin orally. The duration of follow‐up was 90 days. The study authors reported the results of the trial in one publication (<a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>), with the protocol registered at ClinicalTrials.gov retrospectively (NCT02149875). </p> <p>For details of the included trials, see <a href="./references#CD007026-sec-0136" title="">Characteristics of included studies</a>. </p> <p>There are no trials awaiting classification.</p> </section> <section id="CD007026-sec-0048"> <h4 class="title">Excluded studies</h4> <p>In this update of the review we present only the results of the latest search. We excluded one study from the previous list of included trials as not meeting the updated eligibility criteria (<a href="./references#CD007026-bbs2-0011" title="GharagozliK , HarandiAA , HoushmandS , AkbariN , MuresanuDF , VesterJ , et al. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. Journal of Medicine and Life2017;10(3):153-60. IRCT138803272042N1. The efficacy of cerebrolysin in the treatment of acute ischemic stroke. en.irct.ir/trial/1663 (first received 29 August 2009). ">Gharagozli 2017</a>). For details of all studies found, screened, and excluded since the first publication (<a href="./references#CD007026-bbs2-0137" title="ZiganshinaLE , AbakumovaT , KuchaevaA . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub2]">Ziganshina 2010a</a>), please see the previous versions of the review in the version history section, which serves as one particular source of studies (<a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>). </p> <p>With the current search we excluded seven studies reported in nine publications/records, because of: </p> <p> <ul id="CD007026-list-0010"> <li> <p>ineligible study design, including lack of randomisation or control arm;</p> </li> <li> <p>ineligible patient population, including participants with treatment initiation exceeding the protocol‐specified 48 hours after stroke onset and stroke diagnosis not confirmed by neuroimaging. </p> </li> </ul> </p> <p>The reasons for exclusion of these studies are detailed in the <a href="./references#CD007026-sec-0137" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD007026-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>Seven RCTs met the inclusion criteria.</p> <section id="CD007026-sec-0050"> <h4 class="title">Allocation</h4> <p>For sequence generation, we judged one trial to be at low risk of bias (<a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>), and six trials to be at unclear risk of bias because the study authors did not provide any information on sequence generation (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). </p> <p>In <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>, the manufacturer of Cerebrolysin, EVER Neuro Pharma GmbH, provided the randomisation method, which was a computer‐generated randomisation code; we judged this to fit the criteria for low risk of bias. However, we noted the direct involvement of EVER Neuro Pharma with regard to the randomisation codes and the unavailability of the study protocol. </p> <p>In <a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a> and <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>, no information was provided on sequence generation procedures which, combined with the unavailability of a study protocol, resulted in a judgement of unclear risk of bias. </p> <p>We carefully reviewed the published protocol of the <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> study, which was published retrospectively to participant enrolment as <a href="./references#CD007026-bbs2-0077" title="HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12.">Hong 2009</a>, and did not find a description of the procedure for sequence generation, resulting in a judgement of unclear risk of bias. </p> <p>In <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>, the described procedure for sequence generation did not fit the criteria for an assessment of low risk of bias. There was no information about the actual process of generation of a randomisation sequence. In addition, there was a retrospective protocol registration and a statistician contracted by the manufacturer of Cerebrolysin, EVER Neuro Pharma, resulting in a judgement of unclear risk of bias. </p> <p>In <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>, the sequence generation was performed with computer‐generated numbers by a third party; however, it was unclear who the third party was and this, together with the retrospective nature of the trial registration, resulted in a judgement of unclear risk of bias. </p> <p>In <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>, the authors used simple randomisation, however they did not provide details of the sequence generation method. Combined with an unavailable registered study protocol, this resulted in a judgement of unclear risk of bias. </p> <p>For allocation concealment, we judged one trial to be at low risk of bias because they used identical vials (<a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>), and the remaining six included trials to be at unclear risk of bias because the study authors did not provide a clear description of concealment. The exception was <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>, in which the trial authors used sealed envelopes with information on the actual treatment dispensed, and provided these envelopes to the investigator in case of emergency. The published report describes how all envelopes remained sealed throughout the study. However, as the trial authors did not describe the envelopes as opaque, and the trial protocol was unavailable, we judged <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> to be at unclear risk of bias for allocation concealment. </p> </section> <section id="CD007026-sec-0051"> <h4 class="title">Blinding</h4> <p>For blinding of participants and personnel (performance bias), we judged three trials to be at low risk of bias (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>), and the remaining four trials, which did not provide clear information on blinding, as at unclear risk of bias (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). For blinding of outcome assessors (detection bias), we judged three studies to be at low risk of bias (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>), and the remaining four studies to have an unclear risk of bias owing to no or insufficient information to judge low or high risk of bias (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). </p> </section> <section id="CD007026-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>, <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>, and <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> reported no losses to follow‐up and we therefore judged them as having a low risk of attrition bias. The four remaining studies all reported participant losses in excess of 10% (between 16% and 29%, <a href="#CD007026-tbl-0005">Table 4</a>), and we therefore judged them to be at high risk of attrition bias (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). According to publicly available information, all trials included in this meta‐analysis received either unclear or considerable support from the pharmaceutical company that manufactures Cerebrolysin. We judged two studies to be at high risk of other bias owing to the direct involvement of the manufacturer (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>). </p> <div class="table" id="CD007026-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Loss to follow‐up (attrition, missing data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of randomised participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number lost to follow‐up (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number lost to follow‐up</b> </p> <p><b>Cerebrolysin/Cortexin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Number analysed by authors<br/><b>Cerebrolysin/Cortexin</b> (denominator observed case) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number lost to follow‐up</b> </p> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Number analysed by authors<br/><b>Placebo</b> (denominator observed case) </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 + 2 (premature discontinuation) = 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 + 1 (no treatment) = 94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Number lost to follow‐up not stated; we assumed the value to be '0'.</p> </div> </div> <p>The authors of <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> used the 'last observation carried forward' (LOCF) method for their National Institutes of Health Stroke Scale (NIHSS) analysis to fill in their missing data points. There was a 16% loss of participants, but there is no indication as to when these participants were lost, nor for any of the time points is there any indication as to when or how many virtual (i.e. imputed) data were used. It is well understood that using LOCF can introduce bias that may exaggerate the effectiveness of a drug (<a href="./references#CD007026-bbs2-0091" title="MolnarFJ , HuttonB , FergussonD . Does analysis using “last observation carried forward” introduce bias in dementia research?Canadian Medical Association Journal2008;179(8):751-3. [DOI: 10.1503/cmaj.080820]">Molnar 2008</a>; <a href="./references#CD007026-bbs2-0106" title="SalimA , MackinnonA , ChristensenH , GriffithsK . Comparison of data analysis strategies for intent-to-treat analysis in pre-test–post-test designs with substantial dropout rates. Psychiatry Research2008;160(3):335-45. [DOI: 10.1016/j.psychres.2007.08.005]">Salim 2008</a>): "The only condition where LOCF is unbiased is when the missing data occurs completely by chance and the data used as the basis for the LOCF imputation has exactly the same distribution as does the unknown missing data. Since it can never be proven that these distributions are exactly the same, all LOCF analyses are suspect and should be dismissed" (<a href="./references#CD007026-bbs2-0080" title="LachinJM . Fallacies of last observation carried forward. Clinical Trials2016;13(2):161-8. [DOI: 10.1177/1740774515602688]">Lachin 2016</a>). LOCF provides biased results and its use is to be deprecated (<a href="./references#CD007026-bbs2-0080" title="LachinJM . Fallacies of last observation carried forward. Clinical Trials2016;13(2):161-8. [DOI: 10.1177/1740774515602688]">Lachin 2016</a>; <a href="./references#CD007026-bbs2-0091" title="MolnarFJ , HuttonB , FergussonD . Does analysis using “last observation carried forward” introduce bias in dementia research?Canadian Medical Association Journal2008;179(8):751-3. [DOI: 10.1503/cmaj.080820]">Molnar 2008</a>; <a href="./references#CD007026-bbs2-0106" title="SalimA , MackinnonA , ChristensenH , GriffithsK . Comparison of data analysis strategies for intent-to-treat analysis in pre-test–post-test designs with substantial dropout rates. Psychiatry Research2008;160(3):335-45. [DOI: 10.1016/j.psychres.2007.08.005]">Salim 2008</a>). </p> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> also applied LOCF analysis. In this study, 146 participants were randomised, of whom 119 completed the study; 27 participants were therefore lost to follow‐up, but the study authors state that there were only 25 cases lost. Either way, this is a 17% to 18% loss, greater than the 10% that we would find acceptable. The trial authors studied six time points but are silent as to which time points include virtual data or how much virtual data, claiming a complete cohort of N = 146 (despite losing 25 or 27 participants). </p> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> was the only study that compared Cerebrolysin and another neuroprotective agent (NBP). There were 84 participants at the trial initiation; however, data are presented for only 60 participants (20 participants in each of the three comparison groups) without any explanation for the loss of 24 participants (29% attrition). We could not include any data from this study in the quantitative synthesis. </p> </section> <section id="CD007026-sec-0053"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of bias for selective outcome reporting to be unclear for all seven included studies. </p> <p>For four studies there were no protocols in the public domain, with no mention of protocols in the texts of the reports (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). This made it impossible to assess whether the study authors had reported on all of their predefined outcomes. Three studies published their protocols retrospectively (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). </p> <p>The study protocol for <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> was available, and all of the prespecified (primary and secondary) outcomes, which were of interest to the review, were reported accordingly. However, the study authors did not describe the causes of the deaths, and the Kaplan‐Meier mortality curve presented only the subgroup of trial participants with an NIHSS score greater than 12. We judged this study to be at an unclear risk of reporting bias. In their 'Analyses of Mortality', the study authors declared 28 and 32 deaths in the Cerebrolysin and placebo groups, respectively. The hazard ratio is given as 1.26 with a probability of 0.19. The study authors describe this as showing "a small superiority for the Cerebrolysin group". At this level of probability these data show nothing except that there is no difference between groups. Elsewhere in the study the authors claim that probabilities of 0.16 and 0.28 provide evidence in favour of Cerebrolysin in the treatment of ischaemic stroke. The study authors used NIHSS scores and stratified the participants according to scores &gt; 12 and ≤ 12. In their &gt; 12 group, of 252 participants, 12 and 22 Cerebrolysin‐ and placebo‐treated participants died, respectively, with a hazard ratio of 1.9661 and a probability of 0.02485 (notably quoted to five decimal places). It should be noted that among the remaining 815 participants in the ≤ 12 group, 16 and 10 participants in the Cerebrolysin and placebo groups died, respectively. The study authors do not report how many participants were treated with Cerebrolysin or placebo in either the &gt; 12 group or the ≤ 12 group to permit calculation of a hazard ratio, but even so, in a hugely larger number of participants, there is a result that does not favour Cerebrolysin, about which the study authors are silent. </p> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> did not report on the time when the deaths of participants in their trial occurred, and did not assess potential causality with administered medicines. Using the ITT principle, we compared the number of deaths extracted from the safety section of the trial report and presented data as all‐cause death. </p> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> described the causes of deaths (pulmonary embolism, pneumonia, pyelonephritis, and brainstem syndrome secondary to the brain oedema), but without a precise indication of the time when the deaths occurred and a clear indication as to which study group the participants belonged, nor the confirmed cause of death. The study authors did not report on adverse events. The timing of the outcomes presented in a table and a graph in the publication was also unclear. </p> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> reported four deaths among participants who received two courses of Cortexin (4/136), and three deaths in the group of people who received one course of Cortexin and one course of placebo (3/72). There were no deaths in the placebo group (0/64). The authors described the causes of deaths in one of the two identified publications of the trial results: repeated stroke (two), pulmonary embolism (one), polysegmental pneumonia (one) in the Cortexin + Cortexin group; acute intestinal obstruction (one), sudden death (two) in the Cortexin + placebo group. The authors did not indicate the time when the deaths occurred. In all cases, according to the researchers, the deaths were not associated with the study drug. The authors reported the following numbers of adverse events between the groups ‐ 20/136 (14.7%) in the Cortexin + placebo group, 11/72 (15.3%) in the Cortexin + placebo group, and 7/64 (10.9%) in the placebo group. The authors presented their results on post‐stroke functioning using three approaches: Rankin scale, Bartel and Rivermead indices without providing baseline data, and presenting their data only in graphs, which do not allow any extraction of either binary or continuous functional outcomes. We contacted the corresponding author asking for clarification, but did not receive any reply. We made a judgement of unclear risk of bias for selective outcome reporting. </p> </section> <section id="CD007026-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> was stopped because no significant result for the main study outcome was reached. </p> <p>We did not identify any protocol, published or registered, for the trial of the Cerebrolysin‐like agent Cortexin, and the authors did not provide any information on conflicts of interest (<a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>). </p> <p>In both trials, according to the study authors, there was no causal relationship between Cerebrolysin or the Cerebrolysin‐like agent Cortexin and any of the deaths observed (<a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>). Neither the reasons for nor the timing of the deaths was presented. The timing of adverse events and serious adverse events was also not presented. For details, see the risk of bias section of the <a href="./references#CD007026-sec-0136" title="">Characteristics of included studies</a> table. </p> <p>These judgements are illustrated in the risk of bias summary plot (<a href="#CD007026-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD007026-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007026-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> <section id="CD007026-sec-0055"> <h3 class="title" id="CD007026-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD007026-tbl-0001"><b>Summary of findings 1</b> Cerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke</a> </p> <section id="CD007026-sec-0056"> <h4 class="title">Primary outcomes</h4> <section id="CD007026-sec-0057"> <h5 class="title">All‐cause death</h5> <p>The included studies reported on the numbers of deaths in various sections of their trial reports, including in the description of adverse events. We used these data on the numbers of deaths in the comparison groups to generate the primary outcome of all‐cause death. </p> <p>Compared to placebo Cerebrolysin probably results in little to no difference in all‐cause death: there were 46 deaths in the 714 Cerebrolysin‐treated participants and 47 deaths in the 703 placebo‐treated participants: risk ratio (RR) 0.91, 95% confidence interval (CI) 0.61 to 1.34 (5 trials, 1417 participants; moderate‐certainty evidence). The I<sup>2</sup> statistic revealed no heterogeneity: I<sup>2</sup> = 0% (<a href="./references#CD007026-fig-0003" title="">Analysis 1.1</a>). </p> <p>With the addition of the newly identified trial of the Cerebrolysin‐like agent Cortexin, we still found no difference in all‐cause death between the peptide mixture groups and placebo: there were 53 deaths in the 922 peptide‐treated participants and 47 deaths in the 767 placebo‐treated participants (RR 0.96, 95% CI 0.65 to 1.41; 6 trials, 1689 participants; moderate‐certainty evidence). The I<sup>2</sup> statistic revealed no heterogeneity: I<sup>2</sup> = 0% (<a href="./references#CD007026-fig-0003" title="">Analysis 1.1</a>). Sensitivity analysis for worst‐case and best‐case scenarios did not alter the finding of no difference (6 trials, 1689 participants; moderate‐certainty evidence; <a href="./references#CD007026-fig-0009" title="">Analysis 2.1</a>; <a href="./references#CD007026-fig-0010" title="">Analysis 2.2</a>; <a href="./references#CD007026-fig-0011" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD007026-sec-0058"> <h4 class="title">Secondary outcomes</h4> <p>None of the included trials reported on the following clinically important secondary outcomes: poor functional outcome (defined as death or dependence at the end of the follow‐up period), early death (within two weeks of stroke onset), quality of life, or the time to restoration of capacity for work. </p> <section id="CD007026-sec-0059"> <h5 class="title">Cause of death</h5> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>: the causes of death are not described; the authors only mention that one participant in the Cerebrolysin group and two participants in the placebo group died before day 30. The study authors excluded these three participants from their final analysis; we used these data for the all‐cause death assessment. </p> <p><a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>: 28/529 participants randomised to the Cerebrolysin group and 32/541 participants randomised to the placebo group died. The study authors described neither the causes of death nor the times when the deaths occurred. </p> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>: four participants died in each group: 4/60 in the Cerebrolysin group and 4/59 in the placebo group. The study authors described neither the causes of death nor the times when the deaths occurred, and did not find any relationship in any of the cases to the study medication. </p> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>: four out of 136 participants randomised to the first group (Cortexin + Cortexin) and three out of 72 participants randomised to the Cortexin + placebo group died. There were no deaths in the placebo + placebo group (0/64). The study authors reported the following causes of death: repeated stroke (two), pulmonary embolism (one), and polysegmental pneumonia (one) in the Cortexin + Cortexin group; acute intestinal obstruction (one) and sudden death (two) in the Cortexin + placebo group. The authors did not report on the time when the deaths occurred. </p> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>: 6/78 participants in the Cerebrolysin group and 6/68 participants in the placebo group died. The study authors reported on the following causes of death: cerebral infarct (four in the Cerebrolysin group and two in the placebo group), heart failure (two in the Cerebrolysin group and one in the placebo group), pulmonary embolism (two in the placebo group), and pneumonia (one in the placebo group). The trial authors did not report on the times when the deaths occurred. </p> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>: the study authors described the causes of death. They reported the following causes of death not attributed to the stroke: pulmonary embolism, pneumonia, and pyelonephritis in three participants in the Cerebrolysin group and one in the placebo group (not clear which of these), and the causes of death associated with the stroke: brain oedema with secondary brainstem syndrome, which occurred in two participants in both the Cerebrolysin and placebo groups. The deaths occurred within 30 days after the stroke onset, but the study authors did not report precisely on the time of each death. It was unclear to which Cerebrolysin subgroup by dose these participants belonged, 10 mL or 50 mL. </p> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>: one death occurred in the DL‐3‐n‐butylphthalide (NBP) group. </p> </section> <section id="CD007026-sec-0060"> <h5 class="title">Non‐death attrition</h5> <p>We included all six studies that provided numerical results for analysis of non‐death attrition (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). In the Cerebrolysin only subset of data, we found that Cerebrolysin or similar peptide mixtures may result in little to no difference in non‐death attrition, but the evidence is very uncertain: 80 out of 714 Cerebrolysin‐treated participants and 111 out of 703 placebo‐treated participants were lost to follow‐up for reasons other than death (RR 0.72, 95% CI 0.38 to 1.39; 5 trials, 1417 participants; <a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). Combining the Cerebrolysin data with the new <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> study data did not change the results since the study reported no loss to follow‐up (RR 0.72, 95% CI 0.38 to 1.39; 6 trials, 1689 participants; very low‐certainty evidence) (<a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). Three studies reported no loss to follow‐up (no non‐death attrition) (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). There were substantial differences amongst the trials when grouped by Cerebrolysin dose regimen (subgroup differences: P = 0.006) and there was a considerable level of heterogeneity (I<sup>2</sup> = 76%). </p> <p>One study stands out in this analysis. In <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>, we found a lower rate of non‐death attrition in the Cerebrolysin group, with 3 of 78 Cerebrolysin‐treated participants and 10 of 68 placebo‐treated participants being lost to follow‐up (RR 0.26, 95% CI 0.08 to 0.91; P = 0.04; 1 trial, 146 participants; <a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD007026-sec-0061"> <h4 class="title">Adverse events and effects</h4> <section id="CD007026-sec-0062"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>Three trials with a total of 1335 participants contributed to this outcome. We found that Cerebrolysin probably results in little to no difference in the total number of people with SAEs: 58 out of 667 Cerebrolysin‐treated participants and 50 out of 668 placebo‐treated participants (RR 1.16, 95% CI 0.81 to 1.66; 3 trials, 1335 participants; moderate‐certainty evidence; <a href="./references#CD007026-fig-0005" title="">Analysis 1.3</a>). </p> <p>Similarly, we found that Cerebrolysin probably results in little to no difference in the total number of people with fatal SAEs. For fatal SAEs, there were 38/667 and 42/668 in the Cerebrolysin and placebo groups, respectively (RR 0.90, 95% CI 0.59 to 1.38; 3 trials, 1335 participants; moderate‐certainty evidence; <a href="./references#CD007026-fig-0006" title="">Analysis 1.4</a>) and for non‐fatal SAEs: 20/667 and 8/668 participants in the Cerebrolysin and placebo groups, respectively (RR 2.39, 95% CI 1.10 to 5.23; P = 0.03; I<sup>2</sup> = 0%; 3 trials, 1335 participants; moderate‐certainty evidence; <a href="./references#CD007026-fig-0007" title="">Analysis 1.5</a>). Examination of the resulting forest plot revealed opposite directions of effect estimates in the subgroups of different Cerebrolysin dosing regimens (30 mL for 10 days and 50 mL for 21 days) despite a low level of subgroup differences in the overall data synthesis (<a href="./references#CD007026-fig-0007" title="">Analysis 1.5</a>). In the subgroup of the dosing regimen 30 mL for 10 days we found a large difference in the total numbers of people with non‐fatal SAEs treated with Cerebrolysin: 20 out of 589 participants randomised to Cerebrolysin and 7 out of 600 participants randomised to placebo suffered a non‐fatal SAE (RR 2.87, 95% CI 1.24 to 6.69; P = 0.01; 2 trials, 1189 participants; <a href="./references#CD007026-fig-0007" title="">Analysis 1.5</a>). </p> <p>The authors of <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> do not describe the nature of adverse events. In <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>, the study authors did describe SAEs. For the Cerebrolysin‐treated participants these included: acute coronary syndrome, atrial fibrillation, cardiac failure, gastric ulcer, pneumonia (three cases), rectal cancer, coma, pleural effusion, aspiration pneumonia (two cases), cerebral haematoma, and pulmonary embolism. For the placebo‐treated participants these included: cardiac arrest, cardiac failure, hepatic cirrhosis, infective arthritis, pneumonia, sepsis, renal failure, respiratory failure, cerebral haemorrhage, and haemorrhagic stroke (one case each). </p> <p>The <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> study authors reported only one serious non‐fatal adverse event in the placebo group (haematemesis). </p> <p>The authors of <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> did not provide details of how they monitored and registered adverse events. The authors did not specify the numbers of people with certain adverse events (AEs) for the first group; for the second and third groups the authors provided the numbers of occurrences, but it was not clear how many people suffered a specific AE. It was not clear which AEs could be classified as serious AEs, since the authors did not differentiate between AEs of various severities, did not report AEs by severity level, and did not reply to our request for clarification. Thus, we decided not to include <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> in the analysis of SAEs, although some of the reported AEs could be classified as serious. Adverse events in people in the Cortexin + Cortexin group (20 participants) included: recurrent stroke, focal epilepsy, cardiac arrhythmias, acute intestinal obstruction, acute cholecystitis, and urological infection. The authors did not provide the numbers of people with each of the reported AEs. In the Cortexin + placebo group, the authors reported AEs in 11 people, which included cardiac arrhythmias (one), decompensation of coronary heart disease (three), thromboembolic complications (one), pneumonia (one), oncological disease (one), increased activity of liver enzymes in the blood (three), and respiratory infection (one). In the placebo + placebo group the authors described AEs in seven people: progressive course of stroke (two), cardiac arrhythmias (three), mental disorders (two), and subfebrile hyperthermia (one). </p> </section> <section id="CD007026-sec-0063"> <h5 class="title">Total number of people with adverse events</h5> <p>We found information on this outcome in four included studies (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>). The synthesis of the data from these studies revealed no difference between the Cerebrolysin and placebo groups, with 308 of 667 Cerebrolysin‐treated participants and 307 of 668 placebo‐treated participants suffering one or more AEs (RR 1.01, 95% CI 0.91 to 1.13; 3 trials, 1335 participants; <a href="./references#CD007026-fig-0008" title="">Analysis 1.6</a>). Similarly, when including data from <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>, we found that Cerebrolysin or similar peptide mixtures may result in little to no difference in the total number of people with adverse events (RR 1.03, 95% CI 0.92 to 1.14; P = 0.65; 4 trials, 1607 participants; low‐certainty evidence; <a href="./references#CD007026-fig-0008" title="">Analysis 1.6</a>). </p> <p>In <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>, the study authors reported that 242/529 participants in the Cerebrolysin group and 243/541 participants in the placebo group experienced adverse events (RR 1.02, 95% CI 0.89 to 1.16; 1 trial, 1070 participants). </p> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> described the overall evaluation of safety, stating that 88% of Cerebrolysin‐treated participants and 97% of placebo‐treated participants reported at least one adverse event. We recalculated from this for the outcome total number of people with adverse events: 53/60 participants in the Cerebrolysin group and 57/59 participants in the placebo group (RR 0.91, 95% CI 0.82 to 1.01; 1 trial, 119 participants). </p> <p>In <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>, the study authors reported AEs in 20 of 136 participants in the Cortexin + Cortexin group, in 11 of 72 participants in the Cortexin + placebo group, and in 7 of 64 patients (eight occurrences) in the placebo + placebo group (RR 1.38, 95% CI 0.63 to 3.03; 1 trial, 272 participants). Adverse events included: isolated cases of recurrent stroke, focal epilepsy, cardiac arrhythmias, urological infection, acute intestinal obstruction, acute cholecystitis, cardiac arrhythmias, decompensation of coronary heart disease, thromboembolic complications, increased activity of liver enzymes in the blood, pneumonia, respiratory infection, oncological disease, progressive course of stroke, mental disorders, cardiac arrhythmias, and subfebrile hyperthermia. The authors stated that the AEs were not related to the treatment. </p> <p>In <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>, the study authors reported the overall incidence of adverse events: 16.4% in the Cerebrolysin group and 10.3% in the placebo group. We recalculated from this for the outcome total number of people with adverse events: 13/78 participants in the Cerebrolysin group and 7/68 participants in the placebo group (RR 1.62, 95% CI 0.69 to 3.82; 1 trial, 146 participants). The trial authors did not report on any adverse effects specifically associated with Cerebrolysin, for example hypersensitivity reactions. </p> </section> </section> <section id="CD007026-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated potential sources of heterogeneity using the following subgroups of evaluated treatment regimens, which differ by Cerebrolysin dose and length of treatment, for the outcomes all‐cause death, total number of people with adverse events, and total number of people with non‐fatal SAEs. </p> <p> <ul id="CD007026-list-0011"> <li> <p>Cerebrolysin dose 30 mL for 10 days: cumulative dose 300 mL over 10 days (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> did not contribute data to the quantitative analyses. </p> </li> <li> <p>Cerebrolysin dose 50 mL for 21 days: cumulative dose 1050 mL over 21 days (<a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>). </p> </li> <li> <p>Cerebrolysin dose 10 mL or 50 mL for 10 days: cumulative dose 100 mL or 500 mL over 10 days (<a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). </p> </li> </ul> </p> <p>In the Cerebrolysin‐only subset of data for the outcomes all‐cause death, total number of people with SAEs, and total number of people with fatal SAEs, we found no heterogeneity between the subgroups: I<sup>2</sup> = 0% in each case (<a href="./references#CD007026-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD007026-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD007026-fig-0006" title="">Analysis 1.4</a>). In the combined Cerebrolysin or Cortexin analysis we also found no heterogeneity between subgroups for the outcomes all‐cause death or total number of people with AEs (<a href="./references#CD007026-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD007026-fig-0008" title="">Analysis 1.6</a>). </p> <p>For the outcome total number of people with non‐fatal SAEs in the Cerebrolysin‐only subset of data we observed opposing directions of effect estimates in Subgroup 1 (Cerebrolysin dose 30 mL for 10 days: cumulative dose 300 mL over 10 days; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>) versus Subgroup 2 (Cerebrolysin dose 50 mL for 21 days: cumulative dose 1050 mL over 21 days; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>), with the test for subgroup differences revealing an I² value of 46.1% (<a href="./references#CD007026-fig-0007" title="">Analysis 1.5</a>). In Subgroup 1 (the lowest dose amongst all tested doses in the included trials), we found a nearly threefold increase in the incidence of non‐fatal SAEs (RR 2.87, 95% CI 1.24 to 6.69, P = 0.01, I<sup>2</sup> = 0%; 2 trials, 1189 participants). In Subgroup 2 (the highest dose, cumulatively more than three times that of Subgroup 1), the RR was 0.29 with a large range of the confidence interval (95% CI 0.01 to 7.03; P = 0.45; 1 trial, 146 participants). </p> <p>In the Cerebrolysin‐only subset of data we found substantial heterogeneity (I² = 60%) for the outcome total number of people with adverse events amongst the two subgroups of Cerebrolysin dose regimen (30 mL for 10 days; 50 mL for 21 days). It was suggested that the highest dose (cumulatively 1050 mL of Cerebrolysin) and the 21‐day duration might be associated with a higher risk of adverse events, but with an RR of 1.62 (95% CI 0.69 to 3.82; 1 trial, 146 participants), this did not achieve conventional levels of statistical significance (P = 0.27; <a href="./references#CD007026-fig-0008" title="">Analysis 1.6</a>). </p> <p>Heterogeneity was high in the analysis of the outcome non‐death attrition, with I<sup>2</sup> = 57% and I² = 66.4% for subgroup differences (<a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). No one study affected this heterogeneity substantially, and even removing the outermost group from the analysis (<a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>), there is little change of note in either the heterogeneity (which becomes moderate, I<sup>2</sup> = 47%) or the effect of Cerebrolysin (RR 0.87, 95% CI 0.50 to 1.52; P = 0.63; 5 trials, 1543 participants; <a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). </p> </section> <section id="CD007026-sec-0065"> <h4 class="title">Sensitivity analyses</h4> <p>We conducted the sensitivity analyses for the outcome all cause‐death to test the robustness of our methodology and results. </p> <p>To explore the potential effects of missing data we performed a series of sensitivity analyses for worst‐case and best‐case scenarios (as described in <a href="#CD007026-tbl-0002">Table 1</a>). These analyses with corresponding assumptions did not alter the finding of no difference (6 trials, 1689 participants; moderate‐certainty evidence; <a href="./references#CD007026-fig-0009" title="">Analysis 2.1</a>; <a href="./references#CD007026-fig-0010" title="">Analysis 2.2</a>; <a href="./references#CD007026-fig-0011" title="">Analysis 2.3</a>). </p> <p>To explore the potential effect of risk of bias we performed the following analysis. Our judgements of risk of bias both across studies and across risk of bias domains were low, unclear, and high. We were unable to identify studies being at overall high risk of bias. However, we could single out three trials with low risk of attrition bias and unclear risk of bias across the remaining domains (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>) and in this way investigate the effect of study robustness on our primary outcome all‐cause death. Synthesising the outcome data for all‐cause death in these three trials we found a change in the direction of effect to more deaths in people treated with Cerebrolysin or Cerebrolysin‐like peptide mixture Cortexin: there were 15 deaths in the 255 peptide‐treated participants and 5 deaths in the 99 placebo‐treated participants (RR 1.28, 95% CI 0.51 to 3.21; 3 trials, 354 participants; fixed‐effect model). There was no statistical heterogeneity (I<sup>2</sup> = 0%) and the test for subgroup differences also showed no statistical subgroup differences. Changing the fixed‐effect model to the random‐effects model did not affect the result (RR 1.20, 95% CI 0.47 to 3.04; 3 trials, 354 participants; random‐effects model) (<a href="./references#CD007026-fig-0012" title="">Analysis 2.4</a>). These three studies had common characteristics: they had no missing data (loss to follow‐up, non‐death attrition) and they did not report on direct manufacturer involvement. The direction of the effect of peptide mixtures on all‐cause death was reversed in these three trials, favouring placebo. </p> <p>We could not use funnel plots to examine asymmetry and small‐study effects because there were only seven included studies, with six at most contributing data to the quantitative analysis for any given outcome. </p> <p>The use of either a fixed‐effect or random‐effects model made no difference to either direction or value of the effect estimates in any of the analyses, although it might have made a difference to the level of statistical probability of the findings. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007026-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007026-sec-0066"></div> <p>The World Health Organization (WHO) collection of national Essential Medicines Lists (EMLs) includes the latest acting country editions that recommend Cerebrolysin for treating various neurological conditions including acute ischaemic stroke. These include the national EMLs of the Russian Federation (<a href="./references#CD007026-bbs2-0065" title="Government of the Russian Federation. Essential Medicines List for 2019 [Правительство российской федерации]. static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf (accessed prior to 23 June 2020).">GovRu 2019</a>; <a href="./references#CD007026-bbs2-0066" title="Government of the Russian Federation. Corrections to Essential Medicines List for 2019 [Правительство Российской Федерации]. static.government.ru/media/files/gGR64GGr0trcTnxAVXA0y4KwW9iUHGtI.pdf 23 December 2021 (accessed May 2023).">GovRu 2022</a>), Slovakia, Romania, Vietnam, Uganda, and the Syrian Arab Republic (<a href="./references#CD007026-bbs2-0128" title="National Essential Medicines Lists. www.who.int/selection_medicines/country_lists (accessed November 2019).">WHO 2019b</a>; <a href="./references#CD007026-bbs2-0129" title="WHO Global Essential Medicine Lists. https://global.essentialmeds.org/dashboard/medicines (accessed October 2022).">WHO 2022</a>). Cortexin is listed in the national EML (<a href="./references#CD007026-bbs2-0065" title="Government of the Russian Federation. Essential Medicines List for 2019 [Правительство российской федерации]. static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf (accessed prior to 23 June 2020).">GovRu 2019</a>; <a href="./references#CD007026-bbs2-0066" title="Government of the Russian Federation. Corrections to Essential Medicines List for 2019 [Правительство Российской Федерации]. static.government.ru/media/files/gGR64GGr0trcTnxAVXA0y4KwW9iUHGtI.pdf 23 December 2021 (accessed May 2023).">GovRu 2022</a>) and in the clinical guidelines of the Russian Federation together with Cerebrolysin for treating acute ischaemic stroke (<a href="./references#CD007026-bbs2-0090" title="Ministry of Healthcare of the Russian Federation. Cliniсal guidelines. Ischemic stroke and transient ischemic attack in adults [Клинические рекомендации. Ишемический инсульт и транзиторная ишемическая атака у взрослых]. https://cr.minzdrav.gov.ru/schema/171_2 2021 (accessed October 2022).">MinHealthRu 2021</a>). However, the potential benefits of Cerebrolysin or Cortexin for improving clinical outcomes in people with acute ischaemic stroke and the risks of its use have not been demonstrated on the basis of research synthesis of randomised controlled trials (RCTs) of acceptable quality. In this Cochrane Review we have assessed the benefits and harms of Cerebrolysin and the Cerebrolysin‐like agent Cortexin, when added to standard treatment for acute ischaemic stroke, focusing on clinically relevant and widely accepted outcomes, and specifically excluding assessment methods with numerous varying scales. </p> <section id="CD007026-sec-0067"> <h3 class="title" id="CD007026-sec-0067">Summary of main results</h3> <p>Seven RCTs involving 1773 participants met our inclusion criteria. Six studies contributed to the quantitative analyses. </p> <p>In this review update we again confirmed with moderate‐certainty evidence that Cerebrolysin does not substantially alter the risk of death (<a href="./references#CD007026-fig-0003" title="">Analysis 1.1</a>). We also note that the only RCT eligible for inclusion on the Cerebrolysin‐like agent Cortexin presented data on deaths in people treated with Cortexin, while documenting no deaths in participants in the placebo group, despite the less severe stroke in all participants in the trial. When we combined Cerebrolysin and Cortexin data for all‐cause death we established with moderate‐certainty evidence that peptide mixtures do not substantially alter the risk of death (<a href="./references#CD007026-fig-0003" title="">Analysis 1.1</a>). Our sensitivity analysis indicated that the exclusion of trials without a single low risk of bias domain judgement resulted in a change in the direction of effect of peptide mixtures on all‐cause death, with more deaths in the combined Cerebrolysin and Cortexin group. </p> <p>None of the seven included trials provided sufficient evidence of the effects of Cerebrolysin or Cortexin on clinically relevant outcome measures in acute ischaemic stroke, such as poor functional outcome (death or dependence by the end of the follow‐up period) and early death (within two weeks of stroke onset), or time to restoration of capacity for work and quality of life. </p> <p>The authors of only three of the included trials described the causes of death, which could potentially be used for analysis (<a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). In <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>, the causes of death included: cerebral infarct (four in the Cerebrolysin group and two in the placebo group), heart failure (two in the Cerebrolysin group and one in the placebo group), pulmonary embolism (two in the placebo group), and pneumonia (one in the placebo group), with 6/78 deaths in the Cerebrolysin group and 6/68 deaths in the placebo group, although they did not report the time of death. In the newly added study <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>, the authors reported the following causes of deaths: two cases of repeated stroke, one case of pulmonary embolism, and one of polysegmental pneumonia (4/136 deaths) in the Cortexin + Cortexin group, and one acute intestinal obstruction and two sudden deaths (3/72 deaths) in the Cortexin + placebo group; no deaths occurred in placebo + placebo group. The authors did not report the time of the deaths. In <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>, the authors reported the following causes of death not attributed to the stroke: pulmonary embolism, pneumonia, and pyelonephritis (three in the Cerebrolysin group and one in the placebo group), and the causes of death associated with the stroke: brain oedema with secondary brainstem syndrome (two participants in the Cerebrolysin and placebo groups). Owing to unclear numbers we could not synthesise these data. </p> <p>For the outcome non‐death attrition, we did not find a statistical difference between comparison groups. However, the <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> trial stands out in this analysis with a substantially lower rate of non‐death attrition in the Cerebrolysin group (<a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). The obvious main reason is that <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> used a much higher dose of Cerebrolysin (50 mL for 21 days; cumulative dose 1050 mL) than all other trials (cumulative doses ranging from 100 mL to 500 mL over 10 days). Hence, it is not surprising that the sensitivity analyses, which we performed to explore the potential effect of attrition (missing data) on the outcome all‐cause death, did not alter the overall finding of no difference in the outcome all cause‐death between participants with acute ischaemic stroke treated with cattle brain peptide mixtures or placebo (6 trials, 1689 participants; moderate‐certainty evidence). However, the difference in Cerebrolysin dosing regimen does not help us to understand the potential origins of the contrasting non‐death attrition patterns in these two trials. </p> <p>Noteworthy are the results of sensitivity analysis performed to explore the potential effect of risk of bias on the outcome all‐cause death: there was a change in the direction of effect in the three trials with low risk of attrition bias and unclear risk of bias across the remaining domains (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>), compared to the trials with high risk of attrition bias (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>), to more deaths in people treated with Cerebrolysin or Cerebrolysin‐like peptide mixture Cortexin. There were 15 deaths in the 255 peptide‐treated participants and 5 deaths in the 99 placebo‐treated participants (risk ratio (RR) 1.28, 95% confidence interval (CI) 0.51 to 3.21; 3 trials, 354 participants; fixed‐effect model). The direction of the effect of peptide mixtures on all‐cause death in this sensitivity analysis in the three non‐high risk of bias trials was opposite to the high risk of attrition bias trials favouring placebo. The three non‐high risk of bias studies had no missing data (no non‐death attrition) and their authors did not report on direct manufacturer involvement. </p> <p>We confirmed with moderate‐certainty evidence that Cerebrolysin probably makes little to no difference to fatal serious adverse events (SAEs) (<a href="./references#CD007026-fig-0006" title="">Analysis 1.4</a>) and total SAEs (<a href="./references#CD007026-fig-0005" title="">Analysis 1.3</a>). We also found moderate‐certainty evidence that Cerebrolysin likely increases the number of participants with non‐fatal SAEs (<a href="./references#CD007026-fig-0007" title="">Analysis 1.5</a>). </p> <p>By subgrouping two studies with the same dosing schedule (30 mL for 10 days), which contributed data on adverse events and were both multicentre (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>), we confirmed an almost threefold increase in the incidence of non‐fatal SAEs in participants treated with Cerebrolysin, with a resulting number needed to treat to harm (NNTH) of 45, which means that in every 45 acute ischaemic stroke patients treated with Cerebrolysin, one will experience a non‐fatal SAE (<a href="./full#CD007026-tbl-0001">summary of findings Table 1</a>; moderate‐certainty evidence). </p> <p>For the total number of people with adverse events, we did not find a statistical difference between the Cerebrolysin and placebo groups, but identified substantial heterogeneity (I² = 60%) amongst the three Cerebrolysin trials contributing to this outcome (<a href="./references#CD007026-fig-0008" title="">Analysis 1.6</a>). Combining these with the Cortexin data contributed to a lower level of heterogeneity (I² = 38%; <a href="./references#CD007026-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD007026-sec-0068"> <h3 class="title" id="CD007026-sec-0068">Overall completeness and applicability of evidence</h3> <p>In this update we included one new study of the Cerebrolysin‐like agent Cortexin. We followed the protocol in all respects. The new study evaluated participants with acute ischaemic stroke who had been assessed clinically, and the diagnosis was confirmed by neuroimaging (<a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>). </p> <p>The seven eligible studies, four of which were multicentre studies, were carried out in multiple clinical centres in Europe (seven countries): Austria, Croatia, the Czech Republic, Hungary, Russia, Slovakia, and Slovenia; and in Asia (five countries): China, Hong Kong, Iran, Myanmar, and South Korea. The participant populations were geographically diverse. The included studies were conducted in high‐, middle‐, and low‐income countries, which means the results of this Cochrane Review are likely to be applicable to settings where the burden of stroke and stroke deaths is high. Of particular importance is the fact that the results of this update are likely to be applicable to the settings of low‐income countries, where the burden of stroke deaths and disability is even higher (<a href="./references#CD007026-bbs2-0127" title="World Health Organization. The Atlas of Heart Disease and Stroke. www.who.int/cardiovascular_diseases/resources/atlas/en/ (accessed November 2019).">WHO 2019a</a>), and poses a huge financial demand on health systems and society (<a href="./references#CD007026-bbs2-0086" title="MartynchikSA , SokolovaOV . Medical and economic assessment and rationale for improving organization of inpatient care for cerebral stroke [Mediko-ekonomicheskaya otsenka i obosnovaniye sovershenstvovaniya organizatsionnykh form okazaniya statsionarnoy pomoshchi pri mozgovom insul’te]. Sotsial’nyye aspekty zdorov’ya naseleniya [Social Aspects of Population Health ]2013;30(2):e-pub without numbered pages. [vestnik.mednet.ru/content/view/473/30/lang,ru/]">Martynchik 2013</a>), and where Cerebrolysin or Cerebrolysin‐like agents are in widespread use. The included studies tested various doses of Cerebrolysin (10 mL, 30 mL, and 50 mL) and treatment duration with Cerebrolysin varied from 10 days to four weeks. One study tested Cortexin 10 mg twice a day administered in two 10‐day courses with a 10‐day break between the courses. We did not find any clear evidence that Cerebrolysin or Cortexin improves clinical outcomes in acute ischaemic stroke with any of the tested treatment regimens. Treatment strategies for acute ischaemic stroke should be reviewed in light of this evidence. </p> <p>Reporting of data on death and safety parameters without clarification of the time of death or the time of development of adverse events, and the loss of data for many enrolled participants owing to attrition, hampered meaningful interpretation of these data. However, it is apparent that treatment with Cerebrolysin or Cortexin had no beneficial effect on the incidence of death, and may even have had a harmful effect, as demonstrated by the number of deaths in people treated with Cortexin, while Cerebrolysin increased the incidence of non‐fatal SAEs. </p> <p>None of the included studies reported on Cerebrolysin (Cortexin)‐specific, or peptide mixture‐specific, adverse events. These may include: hypersensitivity or emotional disturbance, arousal and aggression; fatigue, tiredness and apathy or sleeplessness; convulsions; rise or fall in blood pressure; shortness of breath; flu‐like syndromes; and reactions on immediate intravenous administration, such as feelings of chills or heat, cold sweats, dizziness and tachycardia, or redness and itching at the site of administration; and gastrointestinal disturbance (<a href="./references#CD007026-bbs2-0098" title="Registry of Medicines. Cerebrolysin [Церебролизин® (Cerebrolysin®)]. www.rlsnet.ru/tn_index_id_3528.htm (accessed prior to 23 June 2020).">Registry of Medicines 2019</a>). </p> </section> <section id="CD007026-sec-0069"> <h3 class="title" id="CD007026-sec-0069">Quality of the evidence</h3> <p>We assessed the certainty of the evidence using the GRADE approach (<a href="./references#CD007026-bbs2-0073" title="GuyattGH , OxmanAD , VistG , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6.">Guyatt 2008</a>), and presented the results in <a href="./full#CD007026-tbl-0001">summary of findings Table 1</a>. For this review we asked the question: should Cerebrolysin or Cerebrolysin‐like agents be used in acute ischaemic stroke to improve clinical outcomes? </p> <p>Based on the six studies that contributed to quantitative analysis and the one trial contributing to qualitative synthesis, there is no evidence that Cerebrolysin or Cerebrolysin‐like agents added to standard therapy reduce deaths in people with acute ischaemic stroke (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). There is moderate‐certainty evidence that Cerebrolysin or Cerebrolysin‐like agents perform no better or worse than placebo in preventing all‐cause death in people with acute ischaemic stroke if started within 48 hours of stroke onset and continued for 10 days to four weeks (<a href="./full#CD007026-tbl-0001">summary of findings Table 1</a>). There is concern from one trial on the Cerebrolysin‐like agent Cortexin that the use of peptide mixtures in acute ischaemic stroke may contribute to deaths. </p> <p>Three studies with a total of 1335 participants, two of which were multicentre, contributed to the outcomes total number of people with SAEs, total number of people with non‐fatal SAEs, and total number of people with adverse events. These studies found 58 SAEs in the Cerebrolysin group (667 randomised participants) and 50 SAEs in the placebo group (668 randomised participants); 20 non‐fatal SAEs in the Cerebrolysin group (667 randomised participants) and 8 non‐fatal SAEs in the placebo group (668 randomised participants); and 308 people with adverse events in the Cerebrolysin group (667 randomised participants) and 307 people with adverse events in the placebo group (668 randomised participants). Although the confidence intervals in <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> were wide and the direction of effect was opposite, this did not result in statistical heterogeneity. </p> <p>Three studies contributed to the outcome total number of people with non‐fatal SAEs, and there is moderate‐certainty evidence that Cerebrolysin likely increases non‐fatal SAEs (but not total SAEs) in people with acute ischaemic stroke (<a href="./references#CD007026-fig-0007" title="">Analysis 1.5</a>). </p> <p>Based on four studies, Cerebrolysin or Cortexin added to standard therapy for acute ischaemic stroke may be no different from placebo in the total number of people with adverse events (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>). There is low‐certainty evidence that Cerebrolysin and similar peptide mixtures perform no better or worse than placebo in terms of the total number of people with adverse events (<a href="./full#CD007026-tbl-0001">summary of findings Table 1</a>). </p> <p>We assessed none of the included studies as being at high risk of bias for all domains. For the majority of the risk of bias domains, such as sequence generation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors, we judged the risk of bias to be low or unclear. Selective outcome reporting was unclear for all seven included studies. High levels of exclusions from the final analyses caused us to assess four studies at high risk of bias for incomplete outcome reporting; three of these studies contributed to quantitative synthesis and all three were multicentre studies, as described in <a href="#CD007026-sec-0034">Assessment of risk of bias in included studies</a> (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>). We judged that these potential limitations were unlikely to lower confidence in the estimate of effect. One of the reasons for judging incomplete outcome reporting as at high risk of bias was the high rate of attrition (<a href="#CD007026-tbl-0005">Table 4</a>); however, despite this, large numbers of participants remained in the trials, and large numbers of effects were reported by the study authors, both for all‐cause death and adverse events. Furthermore, we found no difference between the comparison groups in the numbers of participants lost to follow‐up for reasons other than death, which we analysed as the outcome non‐death attrition, although there was a considerable level of heterogeneity between the subgroups (<a href="./references#CD007026-fig-0004" title="">Analysis 1.2</a>). The new multicentre RCT on the Cerebrolysin‐like agent Cortexin had no losses to follow‐up; it adds to the concerns over the overall safety of peptide mixtures derived from animal brains in people with acute ischaemic stroke. </p> </section> <section id="CD007026-sec-0070"> <h3 class="title" id="CD007026-sec-0070">Potential biases in the review process</h3> <p>We performed the data extraction unblinded.</p> <p>The included trials are published, but we obtained unpublished data on SAEs through feedback received from the manufacturer of Cerebrolysin, EVER Neuro Pharma GmbH (formerly EBEWE Pharma). We were unable to obtain sufficient data on important outcomes such as death or dependency<b>.</b> </p> </section> <section id="CD007026-sec-0071"> <h3 class="title" id="CD007026-sec-0071">Agreements and disagreements with other studies or reviews</h3> <p>We asked whether Cerebrolysin or Cerebrolysin‐like agents have a role in improving treatment outcomes for people diagnosed with acute ischaemic stroke. The original version of this review did not provide evidence that Cerebrolysin was effective (<a href="./references#CD007026-bbs2-0137" title="ZiganshinaLE , AbakumovaT , KuchaevaA . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2010, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub2]">Ziganshina 2010a</a>), and none of the updates since then have shown effectiveness (<a href="./references#CD007026-bbs2-0139" title="ZiganshinaLE , AbakumovaTR . Cerebrolysin for acute ischemic stroke. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk [Bulletin of the Russian Academy of Medical Sciences]2013;1:21-9.">Ziganshina 2013</a>; <a href="./references#CD007026-bbs2-0140" title="ZiganshinaLE , AbakumovaT . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub3]">Ziganshina 2015</a>; <a href="./references#CD007026-bbs2-0141" title="ZiganshinaLE , AbakumovaT , VernayL . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2016, Issue 12. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub4]">Ziganshina 2016</a>; <a href="./references#CD007026-bbs2-0142" title="ZiganshinaLE , AbakumovaT , VernayL . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2017, Issue 4. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub5]">Ziganshina 2017</a>; <a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>). </p> <p>These unfavourable results caution against the widespread use of Cerebrolysin and its inclusion in national Essential Medicines Lists (EMLs) in Russia (<a href="./references#CD007026-bbs2-0065" title="Government of the Russian Federation. Essential Medicines List for 2019 [Правительство российской федерации]. static.government.ru/media/files/K1fPEUszF2gmvwTkw74iPOASarj7KggI.pdf (accessed prior to 23 June 2020).">GovRu 2019</a>; <a href="./references#CD007026-bbs2-0066" title="Government of the Russian Federation. Corrections to Essential Medicines List for 2019 [Правительство Российской Федерации]. static.government.ru/media/files/gGR64GGr0trcTnxAVXA0y4KwW9iUHGtI.pdf 23 December 2021 (accessed May 2023).">GovRu 2022</a>), Ukraine, Romania, Slovakia, Vietnam, Uganda, and the Syrian Arab Republic (<a href="./references#CD007026-bbs2-0128" title="National Essential Medicines Lists. www.who.int/selection_medicines/country_lists (accessed November 2019).">WHO 2019b</a>; <a href="./references#CD007026-bbs2-0129" title="WHO Global Essential Medicine Lists. https://global.essentialmeds.org/dashboard/medicines (accessed October 2022).">WHO 2022</a>). As new research data have accumulated, we have updated the review several times since 2010 after performing new literature searches. The conclusions of the previous version of this Cochrane Review, <a href="./references#CD007026-bbs2-0143" title="ZiganshinaLE , AbakumovaT , HoyleCHV . Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD007026. [DOI: 10.1002/14651858.CD007026.pub6]">Ziganshina 2020</a>, have remained largely unchanged in this update, with the inclusion of a newly identified trial testing the Cerebrolysin‐like agent Cortexin. </p> <p>In contrast to our findings is a recent meta‐analysis of nine trials, which concluded that the safety of Cerebrolysin was comparable to placebo and that Cerebrolysin has a beneficial effect on early global neurological deficits in people with acute ischaemic stroke (<a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a>). Six trials that <a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a> included in their meta‐analysis are also included in this Cochrane Review (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0011" title="GharagozliK , HarandiAA , HoushmandS , AkbariN , MuresanuDF , VesterJ , et al. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. Journal of Medicine and Life2017;10(3):153-60. IRCT138803272042N1. The efficacy of cerebrolysin in the treatment of acute ischemic stroke. en.irct.ir/trial/1663 (first received 29 August 2009). ">Gharagozli 2017</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>; <a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a>). The three studies included in <a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a> that we excluded from our meta‐analysis did not meet our inclusion criteria (<a href="./references#CD007026-bbs2-0069" title="GuekhtA , HeissD , GusevE , VesterJ , DopplerE , MuresanuD . Cerebrolysin and recovery after stroke (CARS 2): a randomized, placebo-controlled, double-blind, multicenter clinical study. Journal of the Neurological Sciences2015;357:e103. [DOI: https://doi.org/10.1016/j.jns.2015.08.336]">Guekht 2015</a>; <a href="./references#CD007026-bbs2-0093" title="MuresanuDF , HeissWD , HoembergV , BajenaruO , PopescuCD , VesterJC , et al. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke2016;47(1):151-9. [DOI: 10.1161/STROKEAHA.115.009416]">Muresanu 2016</a>; <a href="./references#CD007026-bbs2-0115" title="ShamalovNA , StakhovskaiaLV , BurenchevDV , KichukIV , TvorogovaTV , BotsinaAI , et al. The effect of Cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2010;110(12 Pt 2):34-7. [PMID: 21626816]">Shamalov 2010</a>). The <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> trial, which we included in our review, was excluded from <a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a>. </p> <p>An earlier meta‐analysis of nine trials testing Cerebrolysin, Cortexin, and Cellex in ischaemic stroke, vascular dementia, and Alzheimer's disease, published in Russian, also presented contrasting results for Cerebrolysin reducing mortality in stroke, with ambiguous concluding remarks about not being able to "exclude some possible positive effect" of Cerebrolysin (<a href="./references#CD007026-bbs2-0095" title="PlavinskSL , ShabalkinPI . A meta-analysis. Cerebrolisyn, Cortexin, Cellex, efficiency in vascular dementia, Alzheimer's disease and ischemic stroke [Мета-анализ. Церебролизин, Кортексин,Целлекс: эффективность при сосудистой деменции, болезни Альцгеймера и ишемическом инсульте]. In Rus. Zhurnal Medistina (Journal &quot;Medicine&quot;)2016;2:1-15. [https://fsmj.ru/01614.html]">Plavinski 2016</a>). Five trials that <a href="./references#CD007026-bbs2-0095" title="PlavinskSL , ShabalkinPI . A meta-analysis. Cerebrolisyn, Cortexin, Cellex, efficiency in vascular dementia, Alzheimer's disease and ischemic stroke [Мета-анализ. Церебролизин, Кортексин,Целлекс: эффективность при сосудистой деменции, болезни Альцгеймера и ишемическом инсульте]. In Rus. Zhurnal Medistina (Journal &quot;Medicine&quot;)2016;2:1-15. [https://fsmj.ru/01614.html]">Plavinski 2016</a> included in their meta‐analysis are included in this Cochrane Review (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>; <a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a>). Of the four studies included in <a href="./references#CD007026-bbs2-0095" title="PlavinskSL , ShabalkinPI . A meta-analysis. Cerebrolisyn, Cortexin, Cellex, efficiency in vascular dementia, Alzheimer's disease and ischemic stroke [Мета-анализ. Церебролизин, Кортексин,Целлекс: эффективность при сосудистой деменции, болезни Альцгеймера и ишемическом инсульте]. In Rus. Zhurnal Medistina (Journal &quot;Medicine&quot;)2016;2:1-15. [https://fsmj.ru/01614.html]">Plavinski 2016</a> that we excluded from our meta‐analysis, three did not meet our eligibility criteria (<a href="./references#CD007026-bbs2-0093" title="MuresanuDF , HeissWD , HoembergV , BajenaruO , PopescuCD , VesterJC , et al. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke2016;47(1):151-9. [DOI: 10.1161/STROKEAHA.115.009416]">Muresanu 2016</a>; <a href="./references#CD007026-bbs2-0115" title="ShamalovNA , StakhovskaiaLV , BurenchevDV , KichukIV , TvorogovaTV , BotsinaAI , et al. The effect of Cerebrolysin in dosage 50 ml on the volume of lesion in ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2010;110(12 Pt 2):34-7. [PMID: 21626816]">Shamalov 2010</a>; <a href="./references#CD007026-bbs2-0118" title="SkvortsovaVI , StakhovskaiaLV , ShamolovNA , KerbikovOB . Results of the multicenter prospective study of Cerebrolysin safety and efficacy in acute stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2006;Suppl 16:41-5. [PMID: 18196634]">Skvortsova 2006</a>), and one was an economic evaluation. </p> <p>In addition to contrasting with our results, the meta‐analysis <a href="./references#CD007026-bbs2-0040" title="BornsteinNM , GuekhtA , VesterJ , HeissWD , GusevE , HömbergV , et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurological Sciences2018;39(4):629-40. [DOI: 10.1007/s10072-017-3214-0]">Bornstein 2018</a> differs from another recent meta‐analysis that showed lack of benefit from Cerebrolysin treatment for ischaemic stroke compared to placebo for functional recovery at day 90 (<a href="./references#CD007026-bbs2-0123" title="WangZ , ShiL , XuS , ZhangJ . Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy2017;11:1273-82. [DOI: 10.2147/DDDT.S124273]">Wang 2017</a>). Of the six studies included in <a href="./references#CD007026-bbs2-0123" title="WangZ , ShiL , XuS , ZhangJ . Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy2017;11:1273-82. [DOI: 10.2147/DDDT.S124273]">Wang 2017</a>, four overlapped with those included in this Cochrane Review (<a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a>; <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>; <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a>). <a href="./references#CD007026-bbs2-0123" title="WangZ , ShiL , XuS , ZhangJ . Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy2017;11:1273-82. [DOI: 10.2147/DDDT.S124273]">Wang 2017</a> also included studies that we had excluded in a previous revision, as they dealt with different research questions and did not meet our eligibility criteria (CARS study ‐ <a href="./references#CD007026-bbs2-0044" title="ChangWH , ParkCH , KimDY , ShinYI , KoMH , LeeA , et al. Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke. BMC Neurology2016;16:31. [DOI: 10.1186/s12883-016-0553-z]">Chang 2016</a>; <a href="./references#CD007026-bbs2-0093" title="MuresanuDF , HeissWD , HoembergV , BajenaruO , PopescuCD , VesterJC , et al. Cerebrolysin and recovery after stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke2016;47(1):151-9. [DOI: 10.1161/STROKEAHA.115.009416]">Muresanu 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007026-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD007026-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007026-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 1: All‐cause death" data-id="CD007026-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 1: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 2: Non‐death attrition" data-id="CD007026-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 2: Non‐death attrition</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 3: Total number of people with SAEs" data-id="CD007026-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 3: Total number of people with SAEs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 4: Total number of people with fatal SAEs" data-id="CD007026-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 4: Total number of people with fatal SAEs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 5: Total number of people with non‐fatal SAEs" data-id="CD007026-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 5: Total number of people with non‐fatal SAEs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 6: Total number of people with adverse events" data-id="CD007026-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Cerebrolysin or Cortexin versus placebo, Outcome 6: Total number of people with adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 1: All‐cause death. Sensitivity 1. Best‐case" data-id="CD007026-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 1: All‐cause death. Sensitivity 1. Best‐case </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 2: All‐cause death. Sensitivity 2. Worst‐case" data-id="CD007026-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 2: All‐cause death. Sensitivity 2. Worst‐case </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 3: All‐cause death. Sensitivity 3. Complete case (missing data excluded)" data-id="CD007026-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 3: All‐cause death. Sensitivity 3. Complete case (missing data excluded) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007026-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/urn:x-wiley:14651858:media:CD007026:CD007026-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 4: All‐cause death. Sensitivity 4. Risk of bias" data-id="CD007026-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_t/tCD007026-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Sensitivity analyses: Cerebrolysin or Cortexin versus placebo, Outcome 4: All‐cause death. Sensitivity 4. Risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/media/CDSR/CD007026/image_n/nCD007026-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007026-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acute ischaemic stroke<br/><b>Settings:</b> inpatient health facilities<br/><b>Intervention:</b> Cerebrolysin or Cortexin added to standard therapy<br/><b>Comparison:</b> placebo added to standard therapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cerebrolysin/Cortexin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All‐cause death (follow‐up period up to 90 days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> <p>47/767 (6.1%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> <p>53/922 (5.7%)</p> <p><b>3 fewer per 1000</b> </p> <p>(from 22 fewer to 22 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/>(0.65 to 1.41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1689<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Non‐death attrition</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b> </p> <p>111/767 (14.5%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> <p>80/922 (8.7%)</p> <p><b>58 fewer per 1000</b> </p> <p>(from 39 fewer to 152 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.72</b> </p> <p>(0.38 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1689<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Total number of people with SAEs**</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> <p>50/668 (7.5%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> <p>58/667 (8.7%)</p> <p><b>12 more per 1000</b> </p> <p>(from 14 fewer to 47 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.16</b> </p> <p>(0.81 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> <p>42/668 (6.3%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> </p> <p>38/667 (5.7%)</p> <p><b>6 fewer per 1000</b> </p> <p>(from 26 fewer to 24 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b><br/>(0.59 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> <p>8/668 (1.2%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> <p>20/667 (3.0%)</p> <p><b>18 more per 1 000</b> </p> <p>(from 0 fewer to 49 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.39</b> </p> <p>(1.10 to 5.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1335<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total number of people with adverse events, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>429 per 1000</b> </p> <p>314/732 (42.9%)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>387 per 1000</b><br/>339/875 (38.7%) </p> <p><b>42 fewer per 1000</b> </p> <p>(from 38 fewer to 55 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/>(0.92 to 1.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1607<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Death or dependence, follow‐up period up to 90 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Early death (within 2 weeks of stroke onset)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial: <b>RR:</b> risk ratio; <b>SAE:</b> serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>**<b>Results of the subgroup analysis:</b> </p> <p><b>Total number of people with SAEs, non‐fatal</b> </p> <p>A subgroup by Cerebrolysin dose and length of treatment (30 mL for 10 days), at the end of the follow‐up period: assumed risk 12 per 1000 7/600 (1.2%); corresponding risk 33 per 1000 20/589 (3.4%), 22 more per 1000 (from 3 more to 66 more) </p> <p><b>RR 2.86 (1.23 to 6.66)</b>; number of participants (studies) 1189 (2 RCTs) </p> <p>Certainty of the evidence ⊕⊕⊕⊝ <b>Moderate</b><sup>a</sup> </p> <p>_________________________</p> <p><sup>a</sup>We downgraded by one level for risk of bias because most information came from studies at low or unclear risk of bias, with high levels of exclusion from the final analyses, retrospective registration, and other methodological flaws as described in Assessment of risk of bias in included studies. The manufacturer of Cerebrolysin supported <a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> and <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> by providing services including: provision of Cerebrolysin and placebo, randomisation codes, and statisticians. </p> <p><sup>b</sup>We downgraded by one level for inconsistency: heterogeneity with I<sup>2</sup> = 37% for the overall effect estimate owing to the opposite direction of effect estimate in the <a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> study (high cumulative dose of Cerebrolysin), and heterogeneity with I<sup>2</sup> = 65% in the subgroup of two multicentre studies with the same dosing schedule (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>). </p> <p><sup>c</sup>We downgraded by one level for inconsistency and by one level for imprecision. Five trials contributed to the outcome non‐death attrition; we detected heterogeneity, with I<sup>2</sup> = 57% for the overall effect estimate and I<sup>2</sup> = 66% for subgroup differences, and heterogeneity with I<sup>2</sup> = 47% in the subgroup of two multicentre studies with the same dosing schedule (<a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a>; <a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a>). The confidence intervals were wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cerebrolysin or Cerebrolysin‐like agents compared to placebo for acute ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007026-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome all‐cause death and sensitivity analyses</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Nominator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Denominator</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary analysis</p> <p>(Intention‐to‐treat, best‐case)</p> <p>Sensitivity analysis 1 ‐ best‐case</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sensitivity analysis 2 ‐ worst‐case<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included as deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Included</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed case analysis (as per trial authors)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>"Excluded" means removed from the calculation. </p> <p><sup>b</sup>To re‐classify missing participants (missing data, including losses to follow‐up) as treatment failures. For negative outcomes (death) this represents a true worst‐case scenario. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcome all‐cause death and sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007026-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ongoing studies</span></div> <tbody> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Number of</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records identified through database searching (ClinicalTrials.gov and WHO ICTRP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records identified through other sources, namely Russian trial registry (GRLS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duplicates removed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records screened</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Records excluded as irrelevant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial records assessed for eligibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trial records excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in the list of ongoing studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies included in the list of ongoing studies in previous version of review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of studies included in the list of ongoing studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Ongoing studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007026-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NIHSS score at admission</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Baseline score at admission</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin ‐ 14 (13 to 15)</p> <p>Placebo ‐ 14 (12 to 16)</p> <p><i>Median (IQR)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin ‐ 9 (6 to 33)</p> <p>Placebo ‐ 9 (6 to 26)</p> <p><i>Median (range)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin 12.3 (5.39)</p> <p>Placebo 11.0 (5.44)</p> <p><i>Mean (SD)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No info on NIHSS, the Canadian Neurological Scale (CNS) and the Glasgow Coma Scale (GCS) were measured </p> <p>Cerebrolysin ‐ CNS 6.88 (0.09); GCS 14.1 (0.20)</p> <p>Placebo ‐ CNS 6.68 (0.14); 14.4 (0.16)</p> <p><i>Mean (SEM)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin 11.2 ± 4.7</p> <p>Placebo 12.2 ± 2.8</p> <p><i>Mean (±)</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cortexin + Cortexin 7.03 (3.63); 6.0</p> <p>Cortexin + placebo 7.68 (4.94); 6.0</p> <p>Placebo + placebo 7.94 (4.58); 6.0</p> <p><i>Mean (SD); median</i> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cerebrolysin 10.60 (4.74)</p> <p>Placebo 10.20 (3.72)</p> <p><i>Mean (SD)</i> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>IQR: interquartile range<br/>NIHSS: National Institutes of Health Stroke Scale<br/>SD: standard deviation<br/>SEM: standard error of the mean </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">NIHSS score at admission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007026-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Loss to follow‐up (attrition, missing data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of randomised participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number lost to follow‐up (%)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number lost to follow‐up</b> </p> <p><b>Cerebrolysin/Cortexin</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Number analysed by authors<br/><b>Cerebrolysin/Cortexin</b> (denominator observed case) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number lost to follow‐up</b> </p> <p><b>Placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p>Number analysed by authors<br/><b>Placebo</b> (denominator observed case) </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0001" title="Amiri-NikpourMR , NazarbaghiS , Ahmadi-SalmasiB , MokariT , TahamtanU , RezaeiY . Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke. Neuropsychiatric Disease and Treatment2014;10:2299-306. [DOI: 10.2147/NDT.S75304]NazarbaghiS , Amiri NikpoorM . Acute stroke management efficiency of cerebrolysin in treatment of patients with acute ischemic stroke. International Journal of Stroke2014;9 Suppl 3:91-2. ">Amiri Nikpour 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0002" title="BornsteinNM . CASTA - the background for the study and protocol design. International Journal of Stroke2010;5 Suppl 2:50. BraininM , HeissWD , BornsteinN , TuomilehtoJ , HongZ . CASTA - results of a double-blind, placebo-controlled, randomized trial with cerebrolysin on patients with acute ischaemic stroke in Asia. Cerebrovascular Diseases2012;33 Suppl 2:459-60. HeissWD , BraininM , BornsteinN , ZhenH . Cerebrolysin in patients with acute ischemic stroke - the CASTA study. International Journal of Stroke2010;5 Suppl 2:71. HeissWD , BraininM , BornsteinNM , TuomilehtoJ , HongZ , Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke2012;43(3):630-6. HongZ , MoesslerH , BornsteinN , BraininM , Heiss W-D, CASTA Investigators. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. International Journal of Stroke2009;4(5):406-12. NCT00868283. The safety and efficacy of cerebrolysin in patients with acute ischemic stroke (CASTA). clinicaltrials.gov/show/NCT00868283 (first received 24 March 2009). ">CASTA 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 + 2 (premature discontinuation) = 68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 + 1 (no treatment) = 94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0003" title="LangW , StadlerCH , PoljakovicZ , FleetD , Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy combined treatment with alteplase (rt-PA) and cerebrolysin in acute ischaemic hemispheric stroke. International Journal of Stroke2012;8(2):95-104. NCT00840671. Combined treatment with alteplase (Rt-PA) and cerebrolysin® in acute ischemic hemispheric stroke (CERE-LYSE). clinicaltrials.gov/show/NCT00840671 (first received 10 February 2009). ">CERE‐LYSE‐1 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0005" title="LadurnerG , GmeinbauerR , MoesslerH . Cerebrolysin in acute ischaemic stroke: a randomized, placebo-controlled trial with a neuroprotective agent. Cerebrovascular Diseases2001;11(4):75. LadurnerG , KalvachP , MoesslerH , Cerebrolysin Study Group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. Journal of Neural Transmission2005;112(3):415-28. LadurnerG . Neuroprotection in acute ischaemic stroke. Stroke2001;32 Suppl 1:323. ">Ladurner 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0006" title="SkvortsovaVI , ShamalovNA , StakhovskayaLV , GubskyLV , TikhonovaIV , SmichkovAS . Cerebrolysin in acute ischaemic stroke: results of randomised, double blind, placebo-controlled study. Cerebrovascular Diseases2005;19 Suppl 2:76. SkvortsovaVI , StakhovskaiaLV , GubskiiLV , ShamalovNA , TikhonovaIV , SmychkovAS . A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2004;Suppl 11:51-5. SkvortsovaVI , StakhovskayaLV , GubskyLV , ShamalovNA , TikhonovaIV , SmychkovAS . Evaluation of safety and efficacy of cerebrolysin for treating acute ischaemic stroke [Issledovaniye bezopasnosti i effektivnosti tserebrolizina dlya lecheniya ostrogo ishemicheskogo insul’ta]. Рецепт [Prescription]2007;5(55):94-8. ">Skvortsova 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0004" title="AliferovaVM , DadashevaMN , DoroninBM , KovalenkoAV , LokshtanovaTM , Martynov MYu, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke [Клиническая эффективность и фармакоэкономические характеристики нейропротекции низкими дозами кортексина в терапии острого ишемического инсульта]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova [Korsakov Journal of Neurology and Psychiatry]2014;4:41‑6. [ELIBRARY ID: 21538285] [ELIBRARY.RU: https://elibrary.ru/item.asp?id=21538285]StakhovskayaLV , MeshkovaKS , DadashevaMN , Chefranova JYu, TitovaLP , LokshtanovaTM , et al. Results of multicenter randomize prospective double-blind placebo-controlled study of the safety and efficacy of cortexin in acute and subacute periods of hemispheric ischemic stroke [Многоцентровое рандомизированное проспективное двойное слепое плацебо контролируемое исследование безопасности и эффективности кортексина в остром и раннем восстановительном периоде полушарного ишемического инсульта]. Vestnik Rossiiskoy Voenno-Meditsinskoy Academii [Bulletin of the Russian Military Medical Academy]2012;1(37):238-44. [ELIBRARY ID: 17707356] [ELIBRARY.RU: https://www.elibrary.ru/item.asp?id=17707356]">Cortexin‐Shamalov 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007026-bbs2-0007" title="NCT02149875. Dl-3-n-butylphthalide and cerebrolysin treatment in acute ischemic stroke. clinicaltrials.gov/show/NCT02149875 (first received 29 May 2014). XueLX , ZhangT , ZhaoYW , GengZ , ChenJJ , ChenH . Efficacy and safety comparison of DL-3-n-butylphthalide and cerebrolysin: effects on neurological and behavioral outcomes in acute ischemic stroke. Experimental and Therapeutic Medicine2016;11(5):2015-20. ">Xue 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n/a</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Number lost to follow‐up not stated; we assumed the value to be '0'.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Loss to follow‐up (attrition, missing data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/full#CD007026-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007026-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cerebrolysin or Cortexin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.29, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.12, 39.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.17, 59.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Non‐death attrition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.50, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.08, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Total number of people with SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.81, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.83, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.26, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Total number of people with fatal SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.57, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.29, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Total number of people with non‐fatal SAEs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [1.10, 5.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [1.24, 6.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 7.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Total number of people with adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1607</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.92, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Cerebrolysin dose 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.69, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.50, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.42, 3.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Cerebrolysin or Cortexin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007026-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analyses: Cerebrolysin or Cortexin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause death. Sensitivity 1. Best‐case <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.56, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.29, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.12, 39.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.17, 59.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause death. Sensitivity 2. Worst‐case <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.66, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.65, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.24, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.12, 39.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.17, 59.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 All‐cause death. Sensitivity 3. Complete case (missing data excluded) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1496</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.63, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Cerebrolysin dose: 30 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Cerebrolysin dose: 50 mL for 21 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.27, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.37, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.12, 39.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [0.17, 59.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All‐cause death. Sensitivity 4. Risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.65, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Low and unclear risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.51, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 High risk of bias for incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analyses: Cerebrolysin or Cortexin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007026.pub7/references#CD007026-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007026.pub7&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007026-note-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007026-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007026-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007026-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="id#CD007026-note-0013">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD007026-note-0011">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007026-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007026-note-0015">Polski</a> </li> <li class="section-language"> <a class="" href="ro#CD007026-note-0017">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD007026-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007026-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007026\x2epub7"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007026\x2epub7"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007026\x2epub7"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007026\x2epub7\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007026\x2epub7"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007026.pub7&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007026.pub7';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007026.pub7/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007026.pub7/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007026.pub7%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714462143"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007026.pub7/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714462147"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007026.pub7/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6f437f8c9377',t:'MTc0MDcxNDQ2Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 